EU Clinical Trials Register

Clinical trial results:
A Phase III, randomised, double-blind, multicentre, parallel-group, non-inferiority study evaluating the efficacy, safety, and tolerability of dolutegravir plus lamivudine compared to dolutegravir plus tenofovir/emtricitabine in HIV-1-infected treatment-naïve adults

Summary

EudraCT number	2016-000459-28
Trial protocol	DE BE PT ES FR IT
Global end of trial date	29 June 2022

Results information

Result version number	v3 (current)
This version publication date	16 August 2023
First version publication date	13 April 2019
Version creation reason	

Trial information

Trial identification

Sponsor protocol code	205543

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	ViiV Healthcare
Sponsor organisation address	980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS
Public contact	GSK Response Center, ViiV Healthcare, 1 8664357343, GSKClinicalSupportHD@gsk.com
Scientific contact	GSK Response Center, ViiV Healthcare, 1 8664357343, GSKClinicalSupportHD@gsk.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	22 August 2022
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	29 June 2022
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To demonstrate non-inferior antiviral activity of Dolutegravir (DTG) + Lamivudine (3TC) versus DTG + Tenofovir disoproxil fumarate/ Emtricitabine (TDF/FTC) at 48 weeks in human immunodeficiency virus (HIV)-1-infected, Antiretroviral therapy (ART)-naïve participants

Protection of trial subjects:

Not applicable

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	18 July 2016
Long term follow-up planned	Yes
Long term follow-up rationale	Ethical reason
Long term follow-up duration	4 Years
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Argentina: 77
Country: Number of subjects enrolled	Australia: 14
Country: Number of subjects enrolled	Belgium: 8
Country: Number of subjects enrolled	Canada: 13
Country: Number of subjects enrolled	France: 10
Country: Number of subjects enrolled	Germany: 16
Country: Number of subjects enrolled	Italy: 52
Country: Number of subjects enrolled	Mexico: 43
Country: Number of subjects enrolled	Peru: 23
Country: Number of subjects enrolled	Poland: 9
Country: Number of subjects enrolled	Portugal: 20
Country: Number of subjects enrolled	Romania: 21
Country: Number of subjects enrolled	Russian Federation: 87
Country: Number of subjects enrolled	Spain: 98
Country: Number of subjects enrolled	Switzerland: 13
Country: Number of subjects enrolled	Taiwan: 55
Country: Number of subjects enrolled	United States: 135
Country: Number of subjects enrolled	United Kingdom: 28

Worldwide total number of subjects	722
EEA total number of subjects	234

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	719
From 65 to 84 years	3
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

This study is a Phase 3, randomized, double-blind, parallel group, non-inferiority study. The study consisted of double-blind phase, open-label phase and continuation phase.

Pre-assignment

Screening details:

Total of 722 participants were enrolled and randomized; however only 719 participants (3 participants were never dosed following randomization) were dosed in to the study to receive either dolutegravir plus lamivudine (DTG+3TC) or dolutegravir plus tenofovir/emtricitabine (DTG+TDF/FTC) creating the intent to treat-exposed (ITT-E) Population.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
Arm title	DTG + 3TC

Arm description:

Participants received a two-drug regimen of DTG + 3TC administered orally, once daily for 96 weeks in a double-blind phase; from Week 96 to Week 148 in an open-label phase; and from Week 148 to Week 280 in a continuation phase.

Arm type	Experimental
Investigational medicinal product name	Lamivudine (3TC)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

3TC 300 mg capsule, oral administration, once daily.

Investigational medicinal product name	Dolutegravir (DTG)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

DTG 50 mg tablet, oral administration, once daily.

Arm title	DTG + TDF/FTC

Arm description:

Participants received a three-drug regimen of DTG + TDF/FTC fixed dose combination (FDC) administered orally, once daily for 96 weeks in a double-blind phase and from Week 96 to Week 148 in an open-label phase.

Arm type	Active comparator
Investigational medicinal product name	Tenofovir disoproxil fumarate/emtricitabine fixed-dose combination (TDF/FTC)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule

Routes of administration	Oral use

Dosage and administration details:

300 mg TDF/ 200 mg FTC capsule, oral administration, once daily.

Investigational medicinal product name	Dolutegravir (DTG)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

DTG 50 mg tablet, oral administration, once daily.

Number of subjects in period 1[1]	DTG + 3TC	DTG + TDF/FTC
Started	360	359
Completed	288	297
Not completed	72	62
Adverse event, serious fatal	2	1
Consent withdrawn by subject	21	18
Physician decision	9	6
Randomized, but did not receive treatment	-	3
Adverse event, non-fatal	9	11
Protocol Deviation	8	5
Protocol specific withdrawal criteria	1	2
Lost to follow-up	15	14
Lack of efficacy	7	2

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: A total of 722 participants were randomized to receive DTG+3TC and DTG+TDF/FTC. Three participants from DTG+TDF/FTC were randomized, but did not receive treatment. A total of 719 participants received treatment and were included in Intent-to-Treat Exposed (ITT-E) Population.

Baseline characteristics

Reporting groups

Reporting group title	Overall Study

Reporting group description:
Participants received a two-drug regimen of DTG + 3TC administered orally, once daily for 96 weeks in a double-blind phase; from Week 96 to Week 148 in an open-label phase; and from Week 148 to Week 280 in a continuation phase.

Reporting group values	Overall Study	Total	
Number of subjects	719	719	
Age categorical			
Baseline Characteristic data are reported for the Intent-to-Treat Exposed (ITT-E) Population consisted of all randomized participants who received at least one dose of study medication.			
Units: Participants			
Age Continuous			
Baseline Characteristic data are reported for the Intent-to-Treat Exposed (ITT-E) Population consisted of all randomized participants who received at least one dose of study medication.			
Units: years			
arithmetic mean	34.5		
standard deviation	± 10.53	-	
Sex: Female, Male			
Baseline Characteristic data are reported for the Intent-to-Treat Exposed (ITT-E) Population consisted of all randomized participants who received at least one dose of study medication.			
Units: Participants			
Female	100	100	
Male	619	619	
Race/Ethnicity, Customized			
Baseline Characteristic data are reported for the Intent-to-Treat Exposed (ITT-E) Population consisted of all randomized participants who received at least one dose of study medication.			
Units: Subjects			
American (Am) Indian or Alaska (Al.) native	45	45	
Asian-Central/South Asian heritage (H.)	3	3	
Asian - East Asian H.	54	54	
Asian - South East Asian H.	7	7	
Black or African Am	95	95	
Native Hawaiian or other Pacific Islander	5	5	
White (Wt)-Arabic/North African H.	6	6	
Wt-Wt/Caucasian (Ca.)/European (Eu.) H.	480	480	
Am Indian or Al. native and Wt	22	22	
Black or African Am and Wt	2	2	

End points

End points reporting groups

Reporting group title	DTG + 3TC

Reporting group description:

Participants received a two-drug regimen of DTG + 3TC administered orally, once daily for 96 weeks in a double-blind phase; from Week 96 to Week 148 in an open-label phase; and from Week 148 to Week 280 in a continuation phase.

Reporting group title	DTG + TDF/FTC

Reporting group description:

Participants received a three-drug regimen of DTG + TDF/FTC fixed dose combination (FDC) administered orally, once daily for 96 weeks in a double-blind phase and from Week 96 to Week 148 in an open-label phase.

Subject analysis set title	DTG + 3TC - Double-blind Phase + Open-label Phase
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants received a two-drug regimen of DTG + 3TC administered orally, once daily until Week 96 in double-blind phase and participants continued to receive DTG + 3TC from Week 96 to Week 148 in an open-label phase.

Subject analysis set title	DTG + TDF/FTC - Double-blind Phase + Open-label Phase
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants received a three-drug regimen of DTG + TDF/FTC FDC administered orally, once daily until Week 96 in double-blind phase and participants continued to receive DTG + TDF/FTC FDC from Week 96 to Week 148 in an open-label phase.

Subject analysis set title	DTG + 3TC - Double-blind Phase + Open-label Phase
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants received a two-drug regimen of DTG + 3TC administered orally, once daily until Week 96 in double-blind phase and participants continued to receive DTG + 3TC from Week 96 to Week 148 in an open-label phase.

Subject analysis set title	DTG + TDF/FTC - Double-blind Phase + Open-label Phase
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants received a three-drug regimen of DTG + TDF/FTC FDC administered orally, once daily until Week 96 in double-blind phase and participants continued to receive DTG + TDF/FTC FDC from Week 96 to Week 148 in an open-label phase.

Subject analysis set title	DTG + TDF/FTC - Double-blind Phase + Open-label Phase
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants received a three-drug regimen of DTG + TDF/FTC FDC administered orally, once daily until Week 96 in double-blind phase and participants continued to receive DTG + TDF/FTC FDC from Week 96 to Week 148 in an open-label phase.

Subject analysis set title	DTG + 3TC - Double-blind Phase + Open-label Phase
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants received a two-drug regimen of DTG + 3TC administered orally, once daily until Week 96 in double-blind phase and participants continued to receive DTG + 3TC from Week 96 to Week 148 in an open-label phase.

Subject analysis set title	DTG + TDF/FTC - Double-blind Phase + Open-label Phase
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants received a three-drug regimen of DTG + TDF/FTC FDC administered orally, once daily until Week 96 in double-blind phase and participants continued to receive DTG + TDF/FTC FDC from Week 96 to Week 148 in an open-label phase.

Primary: Percentage of participants with plasma Human immunodeficiency virus type 1 (HIV-1) ribonucleic acid (RNA) <50 copies/mL (c/mL) at Week 48

End point title	Percentage of participants with plasma Human immunodeficiency virus type 1 (HIV-1) ribonucleic acid (RNA) <50 copies/mL (c/mL) at Week 48

End point description:

Percentage of participants with HIV-1 RNA<50 c/mL was obtained using Food and Drug Administration (FDA) Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant antiretroviral therapy (ART) prior to the visit of interest. This endpoint was analyzed using a stratified analysis with Cochran-Mantel-Haenszel (CMH) weights. Intent-To-Treat Exposed (ITT-E) Population was used which comprised of all randomized participants who received at least one dose of study treatment. Percentage values are rounded off.

End point type	Primary

End point timeframe:

Week 48

End point values	DTG + 3TC	DTG + TDF/FTC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	360[1]	359[2]		
Units: Percentage of participants				
number (confidence interval 95%)	93 (90.4 to 95.7)	94 (91.4 to 96.4)		

Notes:

[1] - ITT-E Population

[2] - ITT-E Population

Statistical analyses

Statistical analysis title	Statistical Analysis

Statistical analysis description:

Difference in proportion was based on CMH stratified analysis adjusting for Baseline stratification factors: Plasma HIV-1 RNA (<= vs. >100,000 copies per milliliter) and CD4+ cell count (<= vs. >200 cells per cubic millimeter [cells/mm^3]).

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	non-inferiority[3]
Parameter estimate	Adjusted difference in proportion
Point estimate	-0.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.3
upper limit	2.9

Notes:

[3] - Treatment with DTG+ 3TC was to be declared non-inferior to treatment with DTG+TDF/FTC if the lower end of a two-sided 95% confidence interval for the difference between the two groups in response rates at Week 48 was greater than -10%.

Secondary: Percentage of participants with plasma HIV-1 RNA <50 c/mL at Week 24

End point title	Percentage of participants with plasma HIV-1 RNA <50 c/mL at Week 24

End point description:

Percentage of participants with HIV-1 RNA<50 c/mL was obtained using FDA Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. This endpoint was analyzed using a stratified analysis with CMH weights. Percentage values are rounded off.

End point type	Secondary

End point timeframe:

Week 24

End point values	DTG + 3TC	DTG + TDF/FTC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	360[4]	359[5]		
Units: Percentage of participants				
number (confidence interval 95%)	94 (91.4 to 96.4)	94 (91.4 to 96.4)		

Notes:

[4] - ITT-E Population

[5] - ITT-E Population

Statistical analyses

Statistical analysis title	Statistical Analysis

Statistical analysis description:

Difference in proportion was based on CMH stratified analysis adjusting for Baseline stratification factors: Plasma HIV-1 RNA (<= vs. >100,000 c/mL) and CD4+ cell count (<= vs. >200 cells/mm^3).

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	non-inferiority[6]
Parameter estimate	Adjusted difference in proportion
Point estimate	0.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.4
upper limit	3.6

Notes:

[6] - Treatment with DTG+ 3TC was to be declared non-inferior to treatment with DTG+TDF/FTC if the lower end of a two-sided 95% confidence interval for the difference between the two groups in response rates at Week 24 was greater than -10%.

Secondary: Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 96

End point title	Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 96

End point description:

Percentage of participants with HIV-1 RNA<50 c/mL was obtained using FDA Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. This endpoint was

analyzed using a stratified analysis with CMH weights. Percentage values are rounded off.

End point type	Secondary

End point timeframe:
Week 96

End point values	DTG + 3TC	DTG + TDF/FTC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	360[7]	359[8]		
Units: Percentage of participants				
number (confidence interval 95%)	88 (84.4 to 91.2)	90 (86.5 to 92.8)		

Notes:

[7] - ITT-E Population

[8] - ITT-E Population

Statistical analyses

Statistical analysis title	Statistical Analysis

Statistical analysis description:

Week 96. Difference in proportion was based on CMH stratified analysis adjusting for Baseline stratification factors: Plasma HIV-1 RNA (<= vs. >100,000 c/mL) and CD4+ cell count (<= vs. >200 cells/mm^3).

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Adjusted difference in proportion
Point estimate	-1.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.4
upper limit	2.7

Secondary: Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 144

End point title	Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 144

End point description:

Percentage of participants with HIV-1 RNA<50 c/mL was obtained using FDA Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. This endpoint was analyzed using a stratified analysis with CMH weights. Percentage values are rounded off.

End point type	Secondary

End point timeframe:
Week 144

End point values	DTG + 3TC - Double-blind Phase + Open-label Phase	DTG + TDF/FTC - Double-blind Phase + Open-label Phase		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	360[9]	359[10]		
Units: Percentage of participants				
number (confidence interval 95%)	84 (80.4 to 87.9)	84 (80.6 to 88.2)		

Notes:

[9] - ITT-E Population

[10] - ITT-E Population

Statistical analyses

Statistical analysis title	Statistical Analysis

Statistical analysis description:

Week 144. Difference in proportion was based on CMH stratified analysis adjusting for Baseline stratification factors: Plasma HIV-1 RNA (<= vs. >100,000 c/mL) and CD4+ cell count (<= vs. >200 cells/mm^3).

Comparison groups	DTG + 3TC - Double-blind Phase + Open-label Phase v DTG + TDF/FTC - Double-blind Phase + Open-label Phase
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Adjusted difference in proportion
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.3
upper limit	5.3

Secondary: CD4+ cell counts at Weeks 24 and 48

End point title	CD4+ cell counts at Weeks 24 and 48

End point description:

CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+ cells. Analysis was performed by flow cytometry. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Secondary

End point timeframe:

Weeks 24 and 48

End point values	DTG + 3TC	DTG + TDF/FTC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	360[11]	359[12]		
Units: Cells/mm^3				
arithmetic mean (standard deviation)				
Week 24, n=349,345	650.4 (± 257.02)	633.0 (± 287.37)		
Week 48, n=337,340	688.1 (± 266.39)	689.8 (± 308.49)		

Notes:

[11] - ITT-E Population.

[12] - ITT-E Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Time to Viral Suppression (HIV-1 RNA <50 c/mL) up to Week 144

End point title	Time to Viral Suppression (HIV-1 RNA <50 c/mL) up to Week 144

End point description:

Time of viral suppression is defined as the first viral load value <50 c/mL. Nonparametric Kaplan-Meier method was performed. Participants who withdrew for any reason without being suppressed were censored at date of withdrawal. Participants who have not been withdrawn and have not had viral suppression at time of the analysis were censored at last viral load date. Confidence Interval (CI) was estimated using the Brookmeyer-Crowley method.

End point type	Secondary

End point timeframe:

Up to Week 144

End point values	DTG + 3TC - Double-blind Phase + Open-label Phase	DTG + TDF/FTC - Double-blind Phase + Open-label Phase		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	360[13]	359[14]		
Units: Days				
median (inter-quartile range (Q1-Q3))	29.0 (29.0 to 55.0)	29.0 (29.0 to 57.0)		

Notes:

[13] - ITT-E Population

[14] - ITT-E Population

Statistical analyses

Statistical analysis title	Statistical Analysis

Statistical analysis description:

Hazard ratios were estimated using the Cox proportional hazard regression model.

Comparison groups	DTG + 3TC - Double-blind Phase + Open-label Phase v DTG + TDF/FTC - Double-blind Phase + Open-label Phase

Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other[15]
P-value	= 0.797
Method	Generalised Wilcoxon procedure
Parameter estimate	Hazard ratio (HR)
Point estimate	1.02
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.88
upper limit	1.19

Notes:

[15] - The generalised Wilcoxon procedure was used to estimate a p-value for detecting a difference in cumulative incidence curves between treatment groups.

Secondary: CD4+ Cell Counts at Week 144

End point title	CD4+ Cell Counts at Week 144

End point description:

CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+ cells. Analysis was performed by flow cytometry. Only those participants available at the specified time points were analyzed.

End point type	Secondary

End point timeframe:

Week 144

End point values	DTG + 3TC - Double-blind Phase + Open-label Phase	DTG + TDF/FTC - Double-blind Phase + Open-label Phase		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	296[16]	292[17]		
Units: Cells/mm^3				
arithmetic mean (standard deviation)	763.8 (± 266.61)	770.4 (± 332.65)		

Notes:

[16] - ITT-E Population.

[17] - ITT-E Population.

Statistical analyses

No statistical analyses for this end point

Secondary: CD4+ Cell Counts at Week 96

End point title	CD4+ Cell Counts at Week 96

End point description:

CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+ cells. Analysis was performed by flow cytometry. Only those participants available at the specified time points were analyzed.

End point type	Secondary

End point timeframe:

Week 96

End point values	DTG + 3TC	DTG + TDF/FTC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	318[18]	327[19]		
Units: Cells/mm^3				
arithmetic mean (standard deviation)	734.9 (± 270.82)	739.9 (± 299.80)		

Notes:

[18] - ITT-E Population

[19] - ITT-E Population

Statistical analyses

No statistical analyses for this end point

Secondary: Changes from Baseline in CD4+ cell counts at Week 24 and 48

End point title	Changes from Baseline in CD4+ cell counts at Week 24 and 48

End point description:

CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+ cells. Analysis was performed by flow cytometry. Baseline value is defined as the the latest pre-dose assessment. Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted least mean and standard error has been presented. Adjusted mean is the estimated mean change from Baseline at each visit in each arm calculated from a repeated measures model adjusting for the following covariates/factors: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, treatment and visit interaction, and Baseline CD4+ cell count and visit interaction, with visit as the repeated factor. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Secondary

End point timeframe:

Baseline and Weeks 24, 48

End point values	DTG + 3TC	DTG + TDF/FTC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	360[20]	359[21]		
Units: Cells/mm^3				
least squares mean (standard error)				
Week 24, n=349, 345	188.8 (± 8.77)	163.2 (± 9.08)		
Week 48, n=337, 340	225.7 (± 8.94)	217.2 (± 9.93)		

Notes:

[20] - ITT-E Population.

[21] - ITT-E Population.

Statistical analyses

Statistical analysis title	Statistical Analysis 1

Statistical analysis description:

Week 24. Following covariates/factors were adjusted: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, treatment and visit interaction and Baseline CD4+ cell count and visit interaction with visit as the repeated factor.

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.043
Method	Mixed Model Repeated Measures (MMRM)
Parameter estimate	Mean difference (net)
Point estimate	25.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.8
upper limit	50.4

Statistical analysis title	Statistical Analysis 2

Statistical analysis description:

Week 48. Following covariates/factors were adjusted: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, treatment and visit interaction and Baseline CD4+ cell count and visit interaction with visit as the repeated factor.

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.523
Method	MMRM
Parameter estimate	Mean difference (net)
Point estimate	8.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-17.7
upper limit	34.8

Secondary: Changes From Baseline in CD4+ Cell Counts at Week 144

End point title	Changes From Baseline in CD4+ Cell Counts at Week 144

End point description:

CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+ cells. Analysis was performed by flow cytometry. Baseline value is defined as the the latest pre-dose assessment. Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error has been presented. Adjusted mean is the estimated mean change from Baseline at each visit in each arm calculated from a repeated measures model adjusting for the following covariates/factors: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, treatment and visit interaction, and Baseline CD4+ cell count and visit interaction, with visit

as the repeated factor. Only those participants available at the specified time points were analyzed.

End point type	Secondary

End point timeframe:

Baseline and Week 144

End point values	DTG + 3TC - Double-blind Phase + Open-label Phase	DTG + TDF/FTC - Double-blind Phase + Open-label Phase		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	296[22]	292[23]		
Units: Cells/mm^3				
arithmetic mean (standard error)	301.7 (± 11.55)	296.6 (± 13.55)		

Notes:

[22] - ITT-E Population.

[23] - ITT-E Population.

Statistical analyses

Statistical analysis title	Statistical Analysis

Statistical analysis description:

Week 144.Following covariates/factors were adjusted: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, treatment and visit interaction and Baseline CD4+ cell count and visit interaction with visit as the repeated factor.

Comparison groups	DTG + 3TC - Double-blind Phase + Open-label Phase v DTG + TDF/FTC - Double-blind Phase + Open-label Phase
Number of subjects included in analysis	588
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.777
Method	MMRM
Parameter estimate	Mean difference (net)
Point estimate	5.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-29.9
upper limit	40

Secondary: Changes From Baseline in CD4+ Cell Counts at Week 96

End point title	Changes From Baseline in CD4+ Cell Counts at Week 96

End point description:

CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+ cells. Analysis was performed by flow cytometry. Baseline value is defined as the the latest pre-dose assessment. Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error has been presented. Adjusted mean is the estimated mean change from Baseline at each visit in each arm calculated from a repeated measures model adjusting for the following covariates/factors: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+

cell count, treatment and visit interaction, and Baseline CD4+ cell count and visit interaction, with visit as the repeated factor. Only those participants available at the specified time points were analyzed.

End point type	Secondary
End point timeframe:	

Baseline and Week 96

End point values	DTG + 3TC	DTG + TDF/FTC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	318[24]	327[25]		
Units: Cells/mm^3				
arithmetic mean (standard error)	272.0 (± 10.83)	264.6 (± 11.18)		

Notes:

[24] - ITT-E Population.

[25] - ITT-E Population.

Statistical analyses

Statistical analysis title	Statistical Analysis

Statistical analysis description:

Week 96. Following covariates/factors were adjusted: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, treatment and visit interaction and Baseline CD4+ cell count and visit interaction with visit as the repeated factor.

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	645
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.635
Method	Mixed Model Repeated Measures (MMRM)
Parameter estimate	Mean difference (net)
Point estimate	7.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-23.2
upper limit	38

Secondary: Number of Participants With HIV-1 Disease Progression up to Week 144

End point title	Number of Participants With HIV-1 Disease Progression up to Week 144

End point description:

HIV-associated conditions were recorded during the study and was assessed according to the 2014 Centers for Disease Control and Prevention (CDC) Classification System for HIV Infection in Adults. Disease progressions summarize participants who had HIV infection stage 3 associated conditions or death. Indicators of clinical disease progression were defined as: CDC Category Stage 1 at enrollment to Stage 3 event; CDC Category Stage 2 at enrolment to Stage 3 event; CDC Category Stage 3 at enrollment to New Stage 3 Event; CDC Category Stage 1, 2 or 3 at enrolment to Death. Participants may have more than one indicators of clinical disease progression including death, hence they may contribute to data in more than one categories.

End point type	Secondary
End point timeframe:	
Up to Week 144	

End point values	DTG + 3TC - Double-blind Phase + Open-label Phase	DTG + TDF/FTC - Double-blind Phase + Open-label Phase		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	360[26]	359[27]		
Units: Participants				
No disease progression	356	357		
From CDC Stage 1 to CDC Stage 3 Event	0	0		
From CDC Stage 2 to CDC Stage 3 Event	2	1		
From CDC Stage 3 to New CDC Stage 3 Event	1	0		
From CDC Stage 1, 2 or 3 to Death	2	1		

Notes:

[26] - ITT-E Population

[27] - ITT-E Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With Treatment-emergent Genotypic Resistance up to Week 144

End point title	Number of Participants With Treatment-emergent Genotypic Resistance up to Week 144

End point description:

Number of participants, who met confirmed virologic withdrawal (CVW) criteria, with treatment emergent genotypic resistance to Integrase strand transfer inhibitor (INSTI) and/or Nucleoside reverse transcriptase inhibitor (NRTI) was summarized. The Viral Genotypic Population comprised of all participants in the ITT-E population who have available on-treatment genotypic resistance data. Only those participants available at the specified time points were analyzed. The Viral Genotypic Population comprised of all participants in the ITT-E population who have available on-treatment genotypic resistance data.

End point type	Secondary
End point timeframe:	
Up to Week 144	

End point values	DTG + 3TC - Double-blind Phase + Open-label Phase	DTG + TDF/FTC - Double-blind Phase + Open-label Phase		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	7[28]	3[29]		
Units: Participants				

	0	0		
INSTI Mutations	0	0		
Major mutations of the NRTI	0	0		

Notes:

[28] - Viral Genotypic Population.

[29] - Viral Genotypic Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With Treatment-emergent Phenotypic Resistance up to Week 144

End point title	Number of Participants With Treatment-emergent Phenotypic Resistance up to Week 144

End point description:

Number of participants, who met CVW criteria, with treatment emergent phenotypic resistance to INSTI and/or NRTI were summarized. Assessment of antiviral activity of anti-retroviral therapy (ART) using phenotypic test results were interpreted through a proprietary algorithm (from Monogram Biosciences) and provides the overall susceptibility of the drugs (DTG, 3TC, Abacavir [ABC], elvitegravir [EGV], raltegravir [RAL], zidovudine [AZT], stavudine [D4T], didanosine [DDI]), emtricitabine [FTC], tenofovir disiproxil fumarate [TDF]). Partially sensitive and resistant cells were considered resistant in this analysis. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). The Viral Phenotypic Population comprised of all participants in the ITT-E population who have available on-treatment phenotypic resistance data.

End point type	Secondary

End point timeframe:

Up to Week 144

End point values	DTG + 3TC - Double-blind Phase + Open-label Phase	DTG + TDF/FTC - Double-blind Phase + Open-label Phase		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	7[30]	4[31]		
Units: Participants				
INSTI, DTG, Sensitive, n=7,2	7	2		
INSTI, DTG, Resistant, n=7,2	0	0		
INSTI, EGV, Sensitive, n=7,2	7	2		
INSTI, EGV, Resistant, n=7,2	0	0		
INSTI, RAL, Sensitive, n=7,2	7	2		
INSTI, RAL, Resistant, n=7,2	0	0		
NRTI, 3TC, Sensitive, n=7,3	7	3		
NRTI, 3TC, Resistant, n=7,3	0	0		
NRTI, ABC, Sensitive, n=7,3	7	3		
NRTI, ABC, Resistant, n=7,3	0	0		
NRTI, AZT, Sensitive, n=7,3	7	3		
NRTI, AZT, Resistant, n=7,3	0	0		
NRTI, D4T, Sensitive, n=7,3	7	3		
NRTI, D4T, Resistant, n=7,3	0	0		
NRTI, DDI, Sensitive, n=7,3	7	3		
NRTI, DDI, Resistant, n=7,3	0	0		

NRTI, FTC, Sensitive, n=7,3	7	3		
NRTI, FTC, Resistant, n=7,3	0	0		
NRTI, TDF, Sensitive, n=7,3	7	3		
NRTI, TDF, Resistant, n=7,3	0	0		

Notes:

[30] - Viral Phenotypic Population.

[31] - Viral Phenotypic Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With Any AE and SAE up to Week 148

End point title	Number of Participants With Any AE and SAE up to Week 148

End point description:

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention or protocol-defined event associated with liver injury and impaired liver function were categorized as SAE.

End point type	Secondary

End point timeframe:

Up to Week 148

End point values	DTG + 3TC - Double-blind Phase + Open-label Phase	DTG + TDF/FTC - Double-blind Phase + Open-label Phase		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	360[32]	359[33]		
Units: Participants				
Any AE	306	309		
Any SAE	39	47		

Notes:

[32] - Safety Population

[33] - Safety Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With AEs by Maximum Severity Grades up to Week 148

End point title	Number of Participants With AEs by Maximum Severity Grades up to Week 148

End point description:

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs were evaluated by the investigator and graded according to the DAIDS toxicity scales from Grade 1 to 5 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening, 5=Death). The higher the grade, the

more severe the symptoms. Number of participants with adverse events by maximum grade have been presented.

End point type	Secondary
End point timeframe: Up to Week 148	

End point values	DTG + 3TC - Double-blind Phase + Open-label Phase	DTG + TDF/FTC - Double-blind Phase + Open-label Phase		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	360[34]	359[35]		
Units: Participants				
Grade 1 AEs	54	54		
Grade 2 AEs	211	205		
Grade 3 AEs	32	43		
Grade 4 AEs	7	6		
Grade 5 AEs	2	1		

Notes:

[34] - Safety Population

[35] - Safety Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With Any Drug Related AEs and Drug Related AEs by Maximum Grade up to Week 148

End point title	Number of Participants With Any Drug Related AEs and Drug Related AEs by Maximum Grade up to Week 148

End point description:

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs were evaluated by the investigator and graded according to the DAIDS toxicity scales from Grade 1 to 5. (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening, 5=Death). The higher the grade, the more severe the symptoms. Number of participants with drug related AEs and drug related AEs by by maximum grade have been presented.

End point type	Secondary
End point timeframe: Up to Week 148	

End point values	DTG + 3TC - Double-blind Phase + Open-label Phase	DTG + TDF/FTC - Double-blind Phase + Open-label Phase		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	360[36]	359[37]		
Units: Participants				
Any drug related AE	69	91		

Drug related AEs with maximum toxicity Grade 1	37	53		
Drug related AEs with maximum toxicity Grade 2	26	29		
Drug related AEs with maximum toxicity Grade 3	5	8		
Drug related AEs with maximum toxicity Grade 4	1	1		
Drug related AEs with maximum toxicity Grade 5	0	0		

Notes:

[36] - Safety Population

[37] - Safety Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With Maximum Post-Baseline Emergent Hematology Toxicities up to Week 144

End point title	Number of Participants With Maximum Post-Baseline Emergent Hematology Toxicities up to Week 144

End point description:

Blood samples were collected up to Week 144 for assessment of hemoglobin, leukocytes, neutrophils and platelet count. Any abnormality was graded according to DAIDS toxicity scales from Grade 1 to 4 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening). The higher the grade, the more severe the symptoms. Only those participants with maximum post-Baseline emergent hematology toxicities in any of the listed hematology parameters have been presented.

End point type	Secondary

End point timeframe:

Up to Week 144

End point values	DTG + 3TC - Double-blind Phase + Open-label Phase	DTG + TDF/FTC - Double-blind Phase + Open-label Phase		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	360[38]	359[39]		
Units: Participants				
Hemoglobin, Grades 1 to 4	8	10		
Hemoglobin, Grades 2 to 4	6	6		
Hemoglobin, Grades 3 to 4	2	1		
Hemoglobin, Grade 1	2	4		
Hemoglobin, Grade 2	4	5		
Hemoglobin, Grade 3	1	1		
Hemoglobin, Grade 4	1	0		
Leukocytes, Grades 1 to 4	5	5		
Leukocytes, Grades 2 to 4	1	0		
Leukocytes, Grades 3 to 4	0	0		
Leukocytes, Grade 1	4	5		
Leukocytes, Grade 2	1	0		
Leukocytes, Grade 3	0	0		

Leukocytes, Grade 4	0	0		
Neutrophils, Grades 1 to 4	23	7		
Neutrophils, Grades 2 to 4	8	3		
Neutrophils, Grades 3 to 4	4	1		
Neutrophils, Grade 1	15	4		
Neutrophils, Grade 2	4	2		
Neutrophils, Grade 3	2	1		
Neutrophils, Grade 4	2	0		
Platelets, Grades 1 to 4	13	9		
Platelets, Grades 2 to 4	5	5		
Platelets, Grades 3 to 4	0	0		
Platelets, Grade 1	8	4		
Platelets, Grade 2	5	5		
Platelets, Grade 3	0	0		
Platelets, Grade 4	0	0		

Notes:

[38] - Safety Population

[39] - Safety Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With Maximum Post-Baseline Emergent Chemistry Toxicities up to Week 144

End point title	Number of Participants With Maximum Post-Baseline Emergent Chemistry Toxicities up to Week 144

End point description:

Blood samples were collected up to Week 144 for assessment of Alanine Aminotransferase (ALT), Albumin, Alkaline Phosphatase (ALP), Aspartate aminotransferase (AST), Bilirubin, Carbon dioxide (CO_2), Cholesterol, Creatine kinase (CK), Creatinine, Direct Bilirubin, Glomerular filtration rate (GFR), Hypercalcemia, Hyperglycemia, Hyperkalemia, Hypernatremia, Hypocalcemia, Hypoglycemia, Hypokalemia, Hyponatremia, Low density lipid (LDL) Cholesterol, Lactate Dehydrogenase, Lipase, Phosphate, and Triglycerides. Any abnormality was graded according to DAIDS toxicity scales from Grade 1 to 4 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening). The higher the grade, the more severe the symptoms. Only those participants with maximum post-Baseline emergent chemistry toxicities in any of the chemistry parameters have been presented.

End point type	Secondary

End point timeframe:

Up to Week 144

End point values	DTG + 3TC - Double-blind Phase + Open-label Phase	DTG + TDF/FTC - Double-blind Phase + Open-label Phase		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	360[40]	359[41]		
Units: Participants				
ALT, Grades 1 to 4	77	71		
ALT, Grades 2 to 4	30	29		
ALT, Grades 3 to 4	13	15		
ALT, Grade 1	47	42		

ALT, Grade 2	17	14
ALT, Grade 3	6	8
ALT, Grade 4	7	7
Albumin, Grades 1 to 4	2	1
Albumin, Grades 2 to 4	2	1
Albumin, Grades 3 to 4	0	1
Albumin, Grade 1	0	0
Albumin, Grade 2	2	0
Albumin, Grade 3	0	1
Albumin, Grade 4	0	0
ALP, Grades 1 to 4	10	17
ALP, Grades 2 to 4	2	3
ALP, Grades 3 to 4	0	1
ALP, Grade 1	8	14
ALP, Grade 2	2	2
ALP, Grade 3	0	1
ALP, Grade 4	0	0
AST, Grades 1 to 4	71	83
AST, Grades 2 to 4	30	32
AST, Grades 3 to 4	15	14
AST, Grade 1	41	51
AST, Grade 2	15	18
AST, Grade 3	8	11
AST, Grade 4	7	3
Bilirubin, Grades 1 to 4	46	56
Bilirubin, Grades 2 to 4	13	16
Bilirubin, Grades 3 to 4	4	3
Bilirubin, Grade 1	33	40
Bilirubin, Grade 2	9	13
Bilirubin, Grade 3	0	2
Bilirubin, Grade 4	4	1
CO_2, Grades 1 to 4	111	111
CO_2, Grades 2 to 4	10	4
CO_2, Grades 3 to 4	0	0
CO_2, Grade 1	101	107
CO_2, Grade 2	10	4
CO_2, Grade 3	0	0
CO_2, Grade 4	0	0
Cholesterol, Grades 1 to 4	98	50
Cholesterol, Grades 2 to 4	23	12
Cholesterol, Grades 3 to 4	1	0
Cholesterol, Grade 1	75	38
Cholesterol, Grade 2	22	12
Cholesterol, Grade 3	1	0
Cholesterol, Grade 4	0	0
CK, Grades 1 to 4	91	83
CK, Grades 2 to 4	49	47
CK, Grades 3 to 4	29	28
CK, Grade 1	42	36
CK, Grade 2	20	19
CK, Grade 3	11	11
CK, Grade 4	18	17

Creatinine, Grades 1 to 4	18	28		
Creatinine, Grades 2 to 4	5	2		
Creatinine, Grades 3 to 4	0	1		
Creatinine, Grade 1	13	26		
Creatinine, Grade 2	5	1		
Creatinine, Grade 3	0	1		
Creatinine, Grade 4	0	0		
Direct Bilirubin, Grades 1 to 4	11	10		
Direct Bilirubin, Grades 2 to 4	11	10		
Direct Bilirubin, Grades 3 to 4	11	10		
Direct Bilirubin, Grade 1	0	0		
Direct Bilirubin, Grade 2	0	0		
Direct Bilirubin, Grade 3	11	10		
Direct Bilirubin, Grade 4	0	0		
GFR, Grades 1 to 4	198	219		
GFR, Grades 2 to 4	198	219		
GFR, Grades 3 to 4	20	29		
GFR, Grade 1	0	0		
GFR, Grade 2	178	190		
GFR, Grade 3	20	28		
GFR, Grade 4	0	1		
Hypercalcaemia, Grades 1 to 4	4	5		
Hypercalcaemia, Grades 2 to 4	0	1		
Hypercalcaemia, Grades 3 to 4	0	1		
Hypercalcemia, Grade 1	4	4		
Hypercalcaemia, Grade 2	0	0		
Hypercalcaemia, Grade 3	0	0		
Hypercalcaemia, Grade 4	0	1		
Hyperglycaemia, Grades 1 to 4	106	86		
Hyperglycaemia, Grades 2 to 4	49	38		
Hyperglycaemia, Grades 3 to 4	3	3		
Hyperglycaemia, Grade 1	57	48		
Hyperglycaemia, Grade 2	46	35		
Hyperglycaemia, Grade 3	2	2		
Hyperglycaemia, Grade 4	1	1		
Hyperkalemia, Grades 1 to 4	7	7		
Hyperkalemia, Grades 2 to 4	2	1		
Hyperkalemia, Grades 3 to 4	1	1		
Hyperkalemia, Grade 1	5	6		
Hyperkalemia, Grade 2	1	0		
Hyperkalemia, Grade 3	0	1		
Hyperkalemia, Grade 4	1	0		
Hypernatremia, Grades 1 to 4	4	7		
Hypernatremia, Grades 2 to 4	1	0		
Hypernatremia, Grades 3 to 4	0	0		
Hypernatremia, Grade 1	3	7		
Hypernatremia, Grade 2	1	0		
Hypernatremia, Grade 3	0	0		
Hypernatremia, Grade 4	0	0		
Hypocalcaemia, Grades 1 to 4	17	21		
Hypocalcaemia, Grades 2 to 4	6	11		
Hypocalcaemia, Grades 3 to 4	1	3		

Hypocalcaemia, Grade 1	11	10		
Hypocalcaemia, Grade 2	5	8		
Hypocalcaemia, Grade 3	1	2		
Hypocalcaemia, Grade 4	0	1		
Hypoglycaemia, Grades 1 to 4	22	21		
Hypoglycaemia, Grades 2 to 4	6	5		
Hypoglycaemia, Grades 3 to 4	4	1		
Hypoglycaemia, Grade 1	16	16		
Hypoglycaemia, Grade 2	2	4		
Hypoglycaemia, Grade 3	3	0		
Hypoglycaemia, Grade 4	1	1		
Hypokalemia, Grades 1 to 4	9	5		
Hypokalemia, Grades 2 to 4	0	1		
Hypokalemia, Grades 3 to 4	0	0		
Hypokalemia, Grade 1	9	4		
Hypokalemia, Grade 2	0	1		
Hypokalemia, Grade 3	0	0		
Hypokalemia, Grade 4	0	0		
Hyponatremia, Grades 1 to 4	23	22		
Hyponatremia, Grades 2 to 4	0	3		
Hyponatremia, Grades 3 to 4	0	1		
Hyponatremia, Grade 1	23	19		
Hyponatremia, Grade 2	0	2		
Hyponatremia, Grade 3	0	0		
Hyponatremia, Grade 4	0	1		
LDL Cholesterol, Grades 1 to 4	66	40		
LDL Cholesterol, Grades 2 to 4	21	13		
LDL Cholesterol, Grades 3 to 4	6	2		
LDL Cholesterol, Grade 1	45	27		
LDL Cholesterol, Grade 2	15	11		
LDL Cholesterol, Grade 3	6	2		
LDL Cholesterol, Grade 4	0	0		
Lactate Dehydrogenase, Grades 1 to 4	4	2		
Lactate Dehydrogenase, Grades 2 to 4	3	0		
Lactate Dehydrogenase, Grades 3 to 4	0	0		
Lactate Dehydrogenase, Grade 1	1	2		
Lactate Dehydrogenase, Grade 2	3	0		
Lactate Dehydrogenase, Grade 3	0	0		
Lactate Dehydrogenase, Grade 4	0	0		
Lipase, Grades 1 to 4	72	81		
Lipase, Grades 2 to 4	37	43		
Lipase, Grades 3 to 4	9	17		
Lipase, Grade 1	35	38		
Lipase, Grade 2	28	26		
Lipase, Grade 3	6	13		
Lipase, Grade 4	3	4		
Phosphate, Grades 1 to 4	75	78		
Phosphate, Grades 2 to 4	50	51		
Phosphate, Grades 3 to 4	7	7		
Phosphate, Grade 1	25	27		
Phosphate, Grade 2	43	44		
Phosphate, Grade 3	7	7		

Phosphate, Grade 4	0	0
Triglycerides, Grades 1 to 4	89	75
Triglycerides, Grades 2 to 4	22	15
Triglycerides, Grades 3 to 4	4	1
Triglycerides, Grade 1	67	60
Triglycerides, Grade 2	18	14
Triglycerides, Grade 3	4	1
Triglycerides, Grade 4	0	0

Notes:

[40] - Safety Population

[41] - Safety Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants Who Discontinue Treatment Due to AEs Over Weeks 24, 48, 96

End point title	Number of Participants Who Discontinue Treatment Due to AEs Over Weeks 24, 48, 96

End point description:

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants who discontinued treatment due to AEs have been reported.

End point type	Secondary

End point timeframe:

Up to Weeks 24, 48 and 96

End point values	DTG + 3TC	DTG + TDF/FTC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	360[42]	359[43]		
Units: Participants				
Week 24	6	4		
Week 48	8	8		
Week 96	10	12		

Notes:

[42] - Safety Population

[43] - Safety Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants Who Discontinue Treatment Due to AEs Over Week 144

End point title	Number of Participants Who Discontinue Treatment Due to AEs Over Week 144

End point description:

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants who discontinued treatment due to AEs have been reported.

End point type	Secondary
End point timeframe:	
Up to Week 144	

End point values	DTG + 3TC - Double-blind Phase + Open-label Phase	DTG + TDF/FTC - Double-blind Phase + Open-label Phase		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	360[44]	359[45]		
Units: Participants	13	16		

Notes:

[44] - Safety Population

[45] - Safety Population

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in renal biomarkers-Serum Cystatin C and Serum Retinol Binding Protein (RBP) at Weeks 24, 48

End point title	Change from Baseline in renal biomarkers-Serum Cystatin C and Serum Retinol Binding Protein (RBP) at Weeks 24, 48

End point description:

Blood and/or urine samples were collected to perform evaluation of renal biomarkers which included Serum Cystatin C and Serum RBP. Baseline value is the latest pre-dose assessment. Change from Baseline was defined as value at indicated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Secondary
End point timeframe:	
Baseline and at Weeks 24, 48	

End point values	DTG + 3TC	DTG + TDF/FTC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	360[46]	359[47]		
Units: Milligrams per Liter (mg/L)				
least squares mean (standard error)				
Serum Cystatin C, Week 24, n=345,345	-0.04 (± 0.005)	0.00 (± 0.005)		
Serum Cystatin C, Week 48, n=335,336	-0.05 (± 0.005)	-0.04 (± 0.006)		
Serum RBP, Week 24, n=345,343	1.2 (± 0.42)	1.4 (± 0.48)		
Serum RBP, Week 48, n=334, 334	0.6 (± 0.45)	-0.1 (± 0.42)		

Notes:

[46] - Safety Population.

[47] - Safety Population.

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Statistical analysis description:	
Week 24. Serum Cystatin C.	
Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	MMRM
Parameter estimate	Mean difference (net)
Point estimate	-0.03
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.05
upper limit	-0.02

Statistical analysis title	Statistical Analysis 3
Statistical analysis description:	
Week 24. Serum RBP	
Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.797
Method	MMRM
Parameter estimate	Mean difference (net)
Point estimate	-0.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.4
upper limit	1.1

Statistical analysis title	Statistical Analysis 4
Statistical analysis description:	
Week 48. Serum RBP	
Comparison groups	DTG + 3TC v DTG + TDF/FTC

Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.258
Method	MMRM
Parameter estimate	Mean difference (net)
Point estimate	0.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.5
upper limit	1.9

Statistical analysis title	Statistical Analysis 2
Statistical analysis description:	
Week 48. Serum Cystatin C.	
Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.022
Method	MMRM
Parameter estimate	Mean difference (net)
Point estimate	-0.02
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.03
upper limit	0

Secondary: Change From Baseline in Renal Biomarker-Serum Cystatin C at Week 96

End point title	Change From Baseline in Renal Biomarker-Serum Cystatin C at Week 96

End point description:

Blood and/or urine samples were collected to perform evaluation of renal biomarkers which included Serum Cystatin C. Baseline value is the latest pre-dose assessment. Change from Baseline was defined as value at indicated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Adjusted mean and standard error is presented. Only those participants available at the specified time points were analyzed.

End point type	Secondary

End point timeframe:

Baseline and at Week 96

End point values	DTG + 3TC	DTG + TDF/FTC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	316[48]	326[49]		
Units: mg/L				
arithmetic mean (standard error)	-0.09 (± 0.006)	-0.08 (± 0.005)		

Notes:

[48] - Safety Population.

[49] - Safety Population.

Statistical analyses

Statistical analysis title	Statistical Analysis
Statistical analysis description:	
Week 96. Serum Cystatin C.	
Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	642
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.034
Method	MMRM
Parameter estimate	Mean difference (net)
Point estimate	-0.02
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.03
upper limit	0

Secondary: Change From Baseline in Renal Biomarker-Serum Cystatin C at Week 144

End point title	Change From Baseline in Renal Biomarker-Serum Cystatin C at Week 144
End point description:	

Blood and/or urine samples were collected to perform evaluation of renal biomarkers which included Serum Cystatin C. Baseline value is the latest pre-dose assessment. Change from Baseline was defined as value at indicated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Adjusted mean and standard error is presented. Only those participants available at the specified time points were analyzed.

End point type	Secondary
End point timeframe:	
Baseline and at Week 144	

End point values	DTG + 3TC - Double-blind Phase + Open-label Phase	DTG + TDF/FTC - Double-blind Phase + Open-label Phase		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	301[50]	304[51]		
Units: mg/L				
arithmetic mean (standard error)	-0.11 (± 0.005)	-0.08 (± 0.006)		

Notes:

[50] - Safety Population.

[51] - Safety Population.

Statistical analyses

Statistical analysis title	Statistical Analysis
Statistical analysis description:	
Week 144. Serum Cystatin C.	
Comparison groups	DTG + 3TC - Double-blind Phase + Open-label Phase v DTG + TDF/FTC - Double-blind Phase + Open-label Phase
Number of subjects included in analysis	605
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.006
Method	MMRM
Parameter estimate	Mean difference (net)
Point estimate	-0.02
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.04
upper limit	-0.01

Secondary: Change From Baseline in Renal Biomarker-Serum RBP at Week 96

End point title	Change From Baseline in Renal Biomarker-Serum RBP at Week 96
End point description:	

Blood and/or urine samples were collected to perform evaluation of renal biomarkers which included Serum RBP. Baseline value is the latest pre-dose assessment. Change from Baseline was defined as value at indicated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Only those participants available at the specified time points were analyzed.

End point type	Secondary
End point timeframe:	

Baseline and at Week 96

End point values	DTG + 3TC	DTG + TDF/FTC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	314[52]	319[53]		
Units: Microgram per millimoles (ug/mmol)				
arithmetic mean (standard deviation)	0.557 (± 12.7139)	2.483 (± 23.9105)		

Notes:

[52] - Safety Population.

[53] - Safety Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Renal Biomarker-Serum RBP at Week 144

End point title	Change From Baseline in Renal Biomarker-Serum RBP at Week 144

End point description:

Blood and/or urine samples were collected to perform evaluation of renal biomarkers which included Serum RBP. Baseline value is the latest pre-dose assessment. Change from Baseline was defined as value at indicated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Only those participants available at the specified time points were analyzed.

End point type	Secondary

End point timeframe:

Baseline and at Week 144

End point values	DTG + 3TC - Double-blind Phase + Open-label Phase	DTG + TDF/FTC - Double-blind Phase + Open-label Phase		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	294[54]	289[55]		
Units: Microgram per millimoles (ug/mmol)				
arithmetic mean (standard deviation)	0.560 (± 9.5962)	3.813 (± 10.8115)		

Notes:

[54] - Safety Population.

[55] - Safety Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in renal biomarkers-Serum GFR from cystatin C Adjusted using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) and Serum or Plasma GFR from creatinine adjusted using CKD-EPI at Weeks 24, 48

End point title	Change from Baseline in renal biomarkers-Serum GFR from cystatin C Adjusted using Chronic Kidney Disease Epidemiology

	Collaboration (CKD-EPI) and Serum or Plasma GFR from creatinine adjusted using CKD-EPI at Weeks 24, 48

End point description:

Blood samples were collected to perform evaluation of renal biomarkers which included Serum GFR from cystatin C adjusted using CKD-EPI (GFR-cystatin C adjusted) and Serum or Plasma GFR from creatinine adjusted using CKD-EPI. Baseline value is the latest pre-dose Assessment. Change from Baseline was defined as value at the indicated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Secondary

End point timeframe:

Baseline and at Weeks 24, 48

End point values	DTG + 3TC	DTG + TDF/FTC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	360[56]	359[57]		
Units: Milliliter/minute/1.73 meter^2				
arithmetic mean (standard error)				
GFR Cystatin C adjusted, Week 24, n=345,345	3.8 (± 0.66)	0.2 (± 0.65)		
GFR Cystatin C adjusted, Week 48, n=335,336	5.4 (± 0.64)	3.6 (± 0.64)		
GFR creatinine adjusted, Week 24, n=346,344	-12.0 (± 0.64)	-15.4 (± 0.59)		
GFR creatinine adjusted, Week 48, n=335, 337	-12.1 (± 0.60)	-15.4 (± 0.61)		

Notes:

[56] - Safety Population.

[57] - Safety Population.

Statistical analyses

Statistical analysis title	Statistical Analysis 1

Statistical analysis description:

Week 24. GFR Cystatin C adjusted.

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	MMRM
Parameter estimate	Mean difference (net)
Point estimate	3.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.8
upper limit	5.4

Statistical analysis title	Statistical Analysis 3
Statistical analysis description:	
Week 24. GFR creatinine adjusted.	
Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	MMRM
Parameter estimate	Mean difference (net)
Point estimate	3.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.7
upper limit	5.2

Statistical analysis title	Statistical Analysis 4
Statistical analysis description:	
Week 48. GFR creatinine adjusted.	
Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	MMRM
Parameter estimate	Mean difference (net)
Point estimate	3.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.6
upper limit	5

Statistical analysis title	Statistical Analysis 2
Statistical analysis description:	
Week 48. GFR Cystatin C adjusted.	
Comparison groups	DTG + 3TC v DTG + TDF/FTC

Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.056
Method	MMRM
Parameter estimate	Mean difference (net)
Point estimate	1.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	0
upper limit	3.5

Secondary: Change From Baseline in Renal Biomarkers-Serum GFR From Cystatin C Adjusted Using CKD-EPI and Serum or Plasma GFR From Creatinine Adjusted for BSA Using CKD-EPI method at Week 96

End point title	Change From Baseline in Renal Biomarkers-Serum GFR From Cystatin C Adjusted Using CKD-EPI and Serum or Plasma GFR From Creatinine Adjusted for BSA Using CKD-EPI method at Week 96

End point description:

Blood samples were collected to perform evaluation of renal biomarkers which included Serum GFR from cystatin C adjusted using CKD-EPI and Serum or Plasma GFR from creatinine adjusted for BSA using CKD-EPI. Baseline value is the latest pre-dose Assessment. Change from Baseline was defined as value at the indicated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Secondary

End point timeframe:

Baseline and at Week 96

End point values	DTG + 3TC	DTG + TDF/FTC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	360[58]	359[59]		
Units: Milliliter/minute/1.73 meter^2				
arithmetic mean (standard deviation)				
GFR Cystatin C adjusted, Week 96, n=316,326	9.1 (± 18.75)	9.5 (± 13.95)		
GFR creatinine adjusted, Week 96, n=315,325	-14.2 (± 12.69)	-17.5 (± 11.57)		

Notes:

[58] - Safety Population.

[59] - Safety Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Renal Biomarkers-Serum GFR From Cystatin C Adjusted Using CKD-EPI and Serum or Plasma GFR From Creatinine Adjusted for BSA Using CKD-EPI method at Week 144

End point title	Change From Baseline in Renal Biomarkers-Serum GFR From Cystatin C Adjusted Using CKD-EPI and Serum or Plasma GFR From Creatinine Adjusted for BSA Using CKD-EPI method at Week 144

End point description:

Blood samples were collected to perform evaluation of renal biomarkers which included Serum GFR from cystatin C adjusted using CKD-EPI and Serum or Plasma GFR from creatinine adjusted for BSA using CKD-EPI. Baseline value is the latest pre-dose Assessment. Change from Baseline was defined as value at the indicated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Secondary

End point timeframe:

Baseline and at Week 144

End point values	DTG + 3TC - Double-blind Phase + Open-label Phase	DTG + TDF/FTC - Double-blind Phase + Open-label Phase		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	360[60]	359[61]		
Units: Milliliter/minute/1.73 meter^2				
arithmetic mean (standard deviation)				
GFR Cystatin C adjusted, Week 144, n=301,304	10.3 (± 18.82)	10.1 (± 15.50)		
GFR creatinine adjusted, Week 144, n=292,292	-15.5 (± 12.56)	-18.2 (± 11.73)		

Notes:

[60] - Safety Population.

[61] - Safety Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in renal biomarker-Serum or Plasma Creatinine at Weeks 24, 48

End point title	Change from Baseline in renal biomarker-Serum or Plasma Creatinine at Weeks 24, 48

End point description:

Blood and samples were collected to perform evaluation of renal biomarker which included Serum or Plasma Creatinine. Baseline value is defined as the the latest pre-dose assessment. Change from Baseline was calculated as value at the inidcated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Only those participants available at the specified time points were analyzed (represented by n=x in the category titles).

End point type	Secondary

End point timeframe:

Baseline and at Weeks 24, 48

End point values	DTG + 3TC	DTG + TDF/FTC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	360[62]	359[63]		
Units: Micromoles per Liter (umol/L)				
arithmetic mean (standard deviation)				
Serum or Plasma Creatinine, Week 24, n=346, 344	10.51 (± 0.548)	13.53 (± 0.507)		
Serum or Plasma Creatinine, Week 48, n=335, 337	10.32 (± 0.519)	13.44 (± 0.540)		

Notes:

[62] - Safety Population.

[63] - Safety Population.

Statistical analyses

Statistical analysis title	Statistical Analysis 2
Statistical analysis description:	
Week 48. Serum or Plasma creatinine	
Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	MMRM
Parameter estimate	Mean difference (net)
Point estimate	-3.12
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.59
upper limit	-1.65

Statistical analysis title	Statistical Analysis 1
Statistical analysis description:	
Week 24. Serum or Plasma Creatinine	
Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	MMRM
Parameter estimate	Mean difference (net)
Point estimate	-3.02

Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.49
upper limit	-1.55

Secondary: Change From Baseline in Renal Biomarker-Serum or Plasma Creatinine at Week 96

End point title	Change From Baseline in Renal Biomarker-Serum or Plasma Creatinine at Week 96

End point description:

Blood and samples were collected to perform evaluation of renal biomarker which included Serum or Plasma Creatinine. Baseline value is defined as the the latest pre-dose assessment. Change from Baseline was calculated as value at the inidcated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Adjusted mean and standard error has been presented. Only those participants available at the specified time points were analyzed.

End point type	Secondary

End point timeframe:

Baseline and at Week 96

End point values	DTG + 3TC	DTG + TDF/FTC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	315[64]	325[65]		
Units: Micromoles per Liter (umol/L)				
arithmetic mean (standard error)	11.71 (± 0.563)	14.75 (± 0.526)		

Notes:

[64] - Safety Population.

[65] - Safety Population.

Statistical analyses

Statistical analysis title	Statistical Analysis

Statistical analysis description:

Week 96. Serum or Plasma creatinine

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	640
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	MMRM
Parameter estimate	Mean difference (net)
Point estimate	-3.04

Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.56
upper limit	-1.53

Secondary: Change From Baseline in Renal Biomarker-Serum or Plasma Creatinine at Week 144

End point title	Change From Baseline in Renal Biomarker-Serum or Plasma Creatinine at Week 144

End point description:

Blood and samples were collected to perform evaluation of renal biomarker which included Serum or Plasma Creatinine. Baseline value is defined as the the latest pre-dose assessment. Change from Baseline was calculated as value at the inidcated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Adjusted mean and standard error has been presented. Only those participants available at the specified time points were analyzed.

End point type	Secondary

End point timeframe:

Baseline and at Week 144

End point values	DTG + 3TC - Double-blind Phase + Open-label Phase	DTG + TDF/FTC - Double-blind Phase + Open-label Phase		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	292[66]	292[67]		
Units: Micromoles per Liter (umol/L)				
arithmetic mean (standard error)	12.28 (± 0.613)	15.14 (± 0.583)		

Notes:

[66] - Safety Population.

[67] - Safety Population.

Statistical analyses

Statistical analysis title	Statistical Analysis

Statistical analysis description:

Week 144. Serum or Plasma creatinine

Comparison groups	DTG + 3TC - Double-blind Phase + Open-label Phase v DTG + TDF/FTC - Double-blind Phase + Open-label Phase
Number of subjects included in analysis	584
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	MMRM
Parameter estimate	Mean difference (net)
Point estimate	-2.86

Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.52
upper limit	-1.19

Secondary: Ratio to Baseline in renal biomarkers-Urine and Serum Beta-2 Microglobulin (B2M), Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine, Urine RBP 4 and Urine RBP 4/Urine Creatinine at Weeks 24, 48

End point title	Ratio to Baseline in renal biomarkers-Urine and Serum Beta-2 Microglobulin (B2M), Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine, Urine RBP 4 and Urine RBP 4/Urine Creatinine at Weeks 24, 48

End point description:

Blood and/or urine were collected to perform evaluation of renal inflammation biomarkers: Urine and Serum B2M, Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine, Urine RBP 4 and Urine RBP 4/Urine Creatinine. Baseline value was the latest pre-dose assessment. Change from Baseline was performed on log-transformed data. Ratio to Baseline was calculated as ratio of post-dose visit value over Baseline value. Geometric mean ratio and 95% CI of geometric mean ratio have been presented. Biomarkers were Adjusted for treatment, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, loge transformed Baseline biomarker value, treatment and visit interaction, and loge transformed Baseline biomarker value and visit interaction; with visit as the repeated factor. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Secondary

End point timeframe:

Baseline and Weeks 24, 48

End point values	DTG + 3TC	DTG + TDF/FTC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	360[68]	359[69]		
Units: Ratio				
geometric mean (confidence interval 95%)				
Serum B2M, Week 24, n=344,346	0.809 (0.794 to 0.824)	0.882 (0.867 to 0.898)		
Serum B2M, Week 48, n=335,336	0.811 (0.796 to 0.827)	0.887 (0.871 to 0.904)		
Urine B2M, Week 24, n=124,106	0.844 (0.755 to 0.944)	1.129 (0.974 to 1.309)		
Urine B2M, Week 48, n=109, 103	0.917 (0.804 to 1.046)	1.323 (1.066 to 1.642)		
Urine Albumin/Creatinine, Week 24, n=259, 251	0.907 (0.844 to 0.976)	1.021 (0.940 to 1.109)		
Urine Albumin/Creatinine , Week 48, n=249, 240	0.911 (0.835 to 0.994)	0.971 (0.891 to 1.058)		
Urine B2M/Urine Creatinine , Week 24, n=122, 104	0.880 (0.779 to 0.993)	1.126 (0.988 to 1.282)		
Urine B2M/Urine Creatinine , Week 48, n=108, 103	0.969 (0.854 to 1.099)	1.307 (1.077 to 1.586)		

Urine Phosphate, Week 24, n=343, 340	1.041 (0.955 to 1.134)	1.063 (0.978 to 1.157)		
Urine Phosphate, Week 48, n=335, 332	1.121 (1.031 to 1.220)	1.056 (0.974 to 1.144)		
Urine Protein/Creatinine, Week 24, n=263,279	0.818 (0.779 to 0.859)	0.991 (0.941 to 1.043)		
Urine Protein/Creatinine , Week 48, n=259, 261	0.866 (0.818 to 0.917)	1.007 (0.954 to 1.062)		
Urine RBP 4, Week 24, n=340, 338	0.656 (0.591 to 0.729)	0.824 (0.738 to 0.921)		
Urine RBP 4, Week 48, n=333, 331	0.740 (0.666 to 0.822)	0.819 (0.730 to 0.919)		
Urine RBP 4/Urine Creatinine, Week 24, n=338, 335	0.670 (0.614 to 0.730)	0.811 (0.741 to 0.888)		
Urine RBP 4/Urine Creatinine, Week 48, n=331, 328	0.749 (0.689 to 0.814)	0.844 (0.774 to 0.920)		

Notes:

[68] - Safety Population.

[69] - Safety Population.

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Statistical analysis description:	
Week 24. Serum B2M.	
Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	MMRM
Parameter estimate	Ratio of geometric means
Point estimate	0.917
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.893
upper limit	0.941

Statistical analysis title	Statistical Analysis 3
Statistical analysis description:	
Week 24. Urine B2M.	
Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.002
Method	MMRM
Parameter estimate	Ratio of geometric means
Point estimate	0.748

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.621
upper limit	0.901

Statistical analysis title	Statistical Analysis 2
Statistical analysis description:	
Week 48. Serum B2M.	
Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	MMRM
Parameter estimate	Ratio of geometric means
Point estimate	0.914
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.89
upper limit	0.939

Statistical analysis title	Statistical Analysis 7
Statistical analysis description:	
Week 24. Urine B2M/Urine Creatinine.	
Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.007
Method	MMRM
Parameter estimate	Ratio of geometric means
Point estimate	0.781
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.654
upper limit	0.934

Statistical analysis title	Statistical Analysis 6
Statistical analysis description:	
Week 48. Urine Albumin/Creatinine.	
Comparison groups	DTG + 3TC v DTG + TDF/FTC

Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.308
Method	MMRM
Parameter estimate	Ratio of geometric means
Point estimate	0.938
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.83
upper limit	1.061

Statistical analysis title	Statistical Analysis 5

Statistical analysis description:

Week 24. Urine Albumin/Creatinine.

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.036
Method	MMRM
Parameter estimate	Ratio of geometric means
Point estimate	0.889
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.796
upper limit	0.992

Statistical analysis title	Statistical Analysis 4

Statistical analysis description:

Week 48. Urine B2M.

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.005
Method	MMRM
Parameter estimate	Ratio of geometric means
Point estimate	0.693
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.538
upper limit	0.892

Statistical analysis title	Statistical Analysis 8
Statistical analysis description:	
Week 48. Urine B2M/Urine Creatinine.	
Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.012
Method	MMRM
Parameter estimate	Ratio of geometric means
Point estimate	0.742
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.588
upper limit	0.935

Statistical analysis title	Statistical Analysis 13
Statistical analysis description:	
Week 24. Urine RBP 4	
Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.003
Method	MMRM
Parameter estimate	Ratio of geometric means
Point estimate	0.796
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.683
upper limit	0.927

Statistical analysis title	Statistical Analysis 12
Statistical analysis description:	
Week 48. Urine Protein/Creatinine.	
Comparison groups	DTG + 3TC v DTG + TDF/FTC

Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	MMRM
Parameter estimate	Ratio of geometric means
Point estimate	0.86
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.795
upper limit	0.93

Statistical analysis title	Statistical Analysis 9
Statistical analysis description:	
Week 24. Urine Phosphate.	
Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.728
Method	MMRM
Parameter estimate	Ratio of geometric means
Point estimate	0.979
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.868
upper limit	1.104

Statistical analysis title	Statistical Analysis 10
Statistical analysis description:	
Week 48. Urine Phosphate.	
Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.311
Method	MMRM
Parameter estimate	Ratio of geometric means
Point estimate	1.062
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.945
upper limit	1.194

Statistical analysis title	Statistical Analysis 11

Statistical analysis description:

Week 24. Urine Protein/Creatinine.

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	MMRM
Parameter estimate	Ratio of geometric means
Point estimate	0.826
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.769
upper limit	0.887

Statistical analysis title	Statistical Analysis 14

Statistical analysis description:

Week 48. Urine RBP 4

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.2
Method	MMRM
Parameter estimate	Ratio of geometric means
Point estimate	0.903
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.773
upper limit	1.056

Statistical analysis title	Statistical Analysis 15

Statistical analysis description:

Week 24. Urine RBP 4/Urine Creatinine

Comparison groups	DTG + 3TC v DTG + TDF/FTC

Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.003
Method	MMRM
Parameter estimate	Ratio of geometric means
Point estimate	0.826
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.728
upper limit	0.936

Statistical analysis title	Statistical Analysis 16
Statistical analysis description:	
Week 48. Urine RBP 4/Urine Creatinine	
Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.052
Method	MMRM
Parameter estimate	Ratio of geometric means
Point estimate	0.888
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.787
upper limit	1.001

Secondary: Ratio to Baseline in Renal Biomarkers- Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine and Urine RBP 4/Urine Creatinine at Week 96

End point title	Ratio to Baseline in Renal Biomarkers- Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine and Urine RBP 4/Urine Creatinine at Week 96

End point description:

Blood and/or urine were collected to perform evaluation of renal inflammation biomarkers: Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine and Urine RBP 4/Urine Creatinine. Baseline value was the latest pre-dose assessment. Change from Baseline was performed on log-transformed data. Ratio to Baseline was calculated as ratio of post-dose visit value over Baseline value. Biomarkers were Adjusted for treatment, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, loge transformed Baseline biomarker value, treatment and visit interaction, and loge transformed Baseline biomarker value and visit interaction; with visit as the repeated factor. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Secondary

End point timeframe:	
Baseline and Week 96	

End point values	DTG + 3TC	DTG + TDF/FTC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	360[70]	359[71]		
Units: Ratio				
geometric mean (confidence interval 95%)				
Urine Albumin/Creatinine, Week 96, n=239, 243	0.939 (0.861 to 1.023)	0.997 (0.914 to 1.087)		
Urine B2M/Urine Creatinine, Week 96, n=101, 96	0.844 (0.757 to 0.941)	1.259 (1.055 to 1.503)		
Urine Phosphate, Week 96, n=316, 322	1.156 (1.064 to 1.256)	1.069 (0.988 to 1.156)		
Urine Protein/Creatinine, Week 96, n=251, 261	0.887 (0.836 to 0.942)	1.016 (0.963 to 1.072)		
Urine RBP 4/Urine Creatinine, Week 96, n=314, 318	1.030 (0.953 to 1.113)	1.287 (1.189 to 1.393)		

Notes:

[70] - Safety Population.

[71] - Safety Population.

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Statistical analysis description:	
Week 96. Urine Albumin/Creatinine.	
Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.338
Method	MMRM
Parameter estimate	Ratio of geometric means
Point estimate	0.942
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.833
upper limit	1.065

Statistical analysis title	Statistical Analysis 2
Statistical analysis description:	
Week 96. Urine B2M/Urine Creatinine.	
Comparison groups	DTG + 3TC v DTG + TDF/FTC

Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	MMRM
Parameter estimate	Ratio of geometric means
Point estimate	0.671
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.545
upper limit	0.826

Statistical analysis title	Statistical Analysis 5
Statistical analysis description:	
Week 96. Urine RBP 4/Urine Creatinine	
Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	MMRM
Parameter estimate	Ratio of geometric means
Point estimate	0.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.716
upper limit	0.894

Statistical analysis title	Statistical Analysis 4
Statistical analysis description:	
Week 96. Urine Protein/Creatinine.	
Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	MMRM
Parameter estimate	Ratio of geometric means
Point estimate	0.873
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.806
upper limit	0.946

Statistical analysis title	Statistical Analysis 3
Statistical analysis description:	
Week 96. Urine Phosphate.	
Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.174
Method	MMRM
Parameter estimate	Ratio of geometric means
Point estimate	1.082
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.966
upper limit	1.213

Secondary: Ratio to Baseline in Renal Biomarkers- Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine and Urine RBP 4/Urine Creatinine at Week 144

End point title	Ratio to Baseline in Renal Biomarkers- Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine and Urine RBP 4/Urine Creatinine at Week 144

End point description:

Blood and/or urine were collected to perform evaluation of renal inflammation biomarkers: Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine and Urine RBP 4/Urine Creatinine. Baseline value was the latest pre-dose assessment. Change from Baseline was performed on log-transformed data. Ratio to Baseline was calculated as ratio of post-dose visit value over Baseline value. Biomarkers were Adjusted for treatment, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, loge transformed Baseline biomarker value, treatment and visit interaction, and loge transformed Baseline biomarker value and visit interaction; with visit as the repeated factor. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Secondary

End point timeframe:

Baseline and at Week 144

End point values	DTG + 3TC - Double-blind Phase + Open-label Phase	DTG + TDF/FTC - Double-blind Phase + Open-label Phase		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	360[72]	359[73]		
Units: Ratio				
geometric mean (confidence interval				

95%)				
Urine Albumin/Creatinine, Week 144, n=230, 221	1.036 (0.943 to 1.138)	1.067 (0.973 to 1.169)		
Urine B2M/Urine Creatinine, Week 144, n=108, 93	0.872 (0.792 to 0.960)	1.494 (1.266 to 1.762)		
Urine Phosphate, Week 144, n=301, 301	1.083 (1.000 to 1.174)	1.084 (0.999 to 1.175)		
Urine Protein/Creatinine, Week 144, n=236, 246	0.999 (0.947 to 1.054)	1.180 (1.118 to 1.245)		
Urine RBP 4/Urine Creatinine, Week 144, n=294, 289	1.159 (1.083 to 1.240)	1.567 (1.451 to 1.694)		

Notes:

[72] - Safety Population.

[73] - Safety Population.

Statistical analyses

Statistical analysis title	Statistical Analysis 2
Statistical analysis description:	
Week 144. Urine B2M/Urine Creatinine.	
Comparison groups	DTG + 3TC - Double-blind Phase + Open-label Phase v DTG + TDF/FTC - Double-blind Phase + Open-label Phase
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	MMRM
Parameter estimate	Ratio of geometric means
Point estimate	0.584
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.483
upper limit	0.706

Statistical analysis title	Statistical Analysis 1
Statistical analysis description:	
Week 144. Urine Albumin/Creatinine.	
Comparison groups	DTG + 3TC - Double-blind Phase + Open-label Phase v DTG + TDF/FTC - Double-blind Phase + Open-label Phase
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.658
Method	MMRM
Parameter estimate	Ratio of geometric means
Point estimate	0.971
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.852
upper limit	1.107

Statistical analysis title	Statistical Analysis 4
Statistical analysis description:	
Week 144. Urine Protein/Creatinine.	
Comparison groups	DTG + 3TC - Double-blind Phase + Open-label Phase v DTG + TDF/FTC - Double-blind Phase + Open-label Phase
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	MMRM
Parameter estimate	Ratio of geometric means
Point estimate	0.847
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.785
upper limit	0.913

Statistical analysis title	Statistical Analysis 5
Statistical analysis description:	
Week 144. Urine RBP 4/Urine Creatinine	
Comparison groups	DTG + 3TC - Double-blind Phase + Open-label Phase v DTG + TDF/FTC - Double-blind Phase + Open-label Phase
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	MMRM
Parameter estimate	Ratio of geometric means
Point estimate	0.739
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.667
upper limit	0.819

Statistical analysis title	Statistical Analysis 3
Statistical analysis description:	
Week 144. Urine Phosphate.	
Comparison groups	DTG + 3TC - Double-blind Phase + Open-label Phase v DTG + TDF/FTC - Double-blind Phase + Open-label Phase

Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.993
Method	MMRM
Parameter estimate	Ratio of geometric means
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.892
upper limit	1.12

Secondary: Change from Baseline in bone biomarkers-Serum Bone Specific Alkaline Phosphatase (bone-ALP), Serum Osteocalcin, Serum Procollagen 1 N-Terminal Propeptide (PINP) and Serum Type I Collagen C-Telopeptides (CTX-1) at Weeks 24, 48

End point title	Change from Baseline in bone biomarkers-Serum Bone Specific Alkaline Phosphatase (bone-ALP), Serum Osteocalcin, Serum Procollagen 1 N-Terminal Propeptide (PINP) and Serum Type I Collagen C-Telopeptides (CTX-1) at Weeks 24, 48

End point description:

Blood samples were collected to perform evaluation of bone biomarkers which included bone-ALP, Serum Osteocalcin, PINP and CTX-1. Adjusted mean and standard error is presented. Adjusted mean is the estimated mean change from Baseline at each visit in each arm calculated from a repeated measures model adjusting for: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count (factor), age, sex (factor), race (factor), BMI (factor), smoking status (factor), current Vitamin D use (factor), Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Baseline value is defined as the latest pre-dose assessment. Change from Baseline was calculated as value at the indicated time point minus Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Secondary

End point timeframe:

Baseline (Day 1) and at Weeks 24, 48

End point values	DTG + 3TC	DTG + TDF/FTC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	360[74]	359[75]		
Units: Micrograms per Liter (ug/L)				
arithmetic mean (standard error)				
Bone-ALP, Week 24, n=345, 346	0.72 (± 0.171)	3.38 (± 0.244)		
Bone-ALP, Week 48, n=334, 337	1.24 (± 0.198)	4.33 (± 0.268)		
Serum Osteocalcin, Week 24, n=345, 346	2.13 (± 0.321)	6.80 (± 0.368)		
Serum Osteocalcin, Week 48, n=335, 336	0.40 (± 0.326)	6.30 (± 0.384)		
PINP, Week 24, n=344, 346	1.7 (± 0.95)	15.2 (± 1.12)		
PINP, Week 48, n=335, 337	0.4 (± 0.79)	13.3 (± 1.06)		

CTX-1, Week 24, n=342, 342	0.1541 (± 0.01247)	0.2812 (± 0.01406)		
CTX-1, Week 48, n=332, 333	0.1345 (± 0.01496)	0.3388 (± 0.01983)		

Notes:

[74] - Safety Population.

[75] - Safety Population.

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Statistical analysis description:	
Week 24, Bone ALP	
Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	MMRM
Parameter estimate	Mean difference (net)
Point estimate	-2.66
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.25
upper limit	-2.08

Statistical analysis title	Statistical Analysis 2
Statistical analysis description:	
Week 48, Bone ALP	
Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	MMRM
Parameter estimate	Mean difference (net)
Point estimate	-3.09
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.75
upper limit	-2.44

Statistical analysis title	Statistical Analysis 3
Statistical analysis description:	
Week 28, Serum Osteocalcin	

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	MMRM
Parameter estimate	Mean difference (net)
Point estimate	-4.67
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.63
upper limit	-3.71

Statistical analysis title	Statistical Analysis 4
Statistical analysis description:	
Week 48, Serum Osteocalcin	
Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	MMRM
Parameter estimate	Mean difference (net)
Point estimate	-5.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.89
upper limit	-4.91

Statistical analysis title	Statistical Analysis 5
Statistical analysis description:	
Week 24, Serum PINP	
Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	MMRM
Parameter estimate	Mean difference (net)
Point estimate	-13.5

Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.4
upper limit	-10.6

Statistical analysis title	Statistical Analysis 6
Statistical analysis description:	
Week 48, Serum PINP	
Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	MMRM
Parameter estimate	Mean difference (net)
Point estimate	-12.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-15.4
upper limit	-10.2

Statistical analysis title	Statistical Analysis 7
Statistical analysis description:	
Week 24, CTX-1	
Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	MMRM
Parameter estimate	Mean difference (net)
Point estimate	-0.127
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.164
upper limit	-0.09

Statistical analysis title	Statistical Analysis 8
Statistical analysis description:	
Week 48, CTX-1	
Comparison groups	DTG + 3TC v DTG + TDF/FTC

Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	MMRM
Parameter estimate	Mean difference (net)
Point estimate	-0.2043
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.2532
upper limit	-0.1554

Secondary: Change From Baseline in Bone Biomarkers-Serum Bone-ALP, Serum Osteocalcin, Serum PINP and Serum Type I CTX-1 at Week 96

End point title	Change From Baseline in Bone Biomarkers-Serum Bone-ALP, Serum Osteocalcin, Serum PINP and Serum Type I CTX-1 at Week 96

End point description:

Blood samples were collected to perform evaluation of bone biomarkers which included bone-ALP, Serum Osteocalcin, Serum PINP and Serum Type CTX-1. Adjusted mean is the estimated mean change from Baseline in each arm calculated from a repeated measures model adjusting for: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count (factor), age, sex (factor), race (factor), BMI (factor), smoking status (factor), current vitamin D use (factor), Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Baseline value is defined as the latest pre-dose assessment. Change from Baseline was calculated as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Secondary

End point timeframe:

Baseline (Day 1) and at Week 96

End point values	DTG + 3TC	DTG + TDF/FTC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	360[76]	359[77]		
Units: Micrograms per Liter (ug/L)				
arithmetic mean (standard error)				
Bone-ALP, Week 96, n=315, 326	0.26 (± 0.188)	2.39 (± 0.234)		
Serum Osteocalcin, Week 96, n=315, 326	0.13 (± 0.286)	3.90 (± 0.368)		
PINP, Week 96, n=315, 325	7.0 (± 1.37)	19.5 (± 1.66)		
CTX-1, Week 96, n=311, 318	0.0604 (± 0.01056)	0.1787 (± 0.01403)		

Notes:

[76] - Safety Population.

[77] - Safety Population.

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Statistical analysis description: Week 96, Bone ALP	
Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	MMRM
Parameter estimate	Mean difference (net)
Point estimate	-2.13
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.72
upper limit	-1.54

Statistical analysis title	Statistical Analysis 4
Statistical analysis description: Week 96, CTX-1	
Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	MMRM
Parameter estimate	Mean difference (net)
Point estimate	-0.1183
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.1529
upper limit	-0.0838

Statistical analysis title	Statistical Analysis 3
Statistical analysis description: Week 96, Serum PINP	
Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	MMRM
Parameter estimate	Mean difference (net)
Point estimate	-12.6

Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.8
upper limit	-8.3

Statistical analysis title	Statistical Analysis 2
Statistical analysis description:	
Week 96, Serum Osteocalcin	
Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	MMRM
Parameter estimate	Mean difference (net)
Point estimate	-3.77
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.69
upper limit	-2.85

Secondary: Change From Baseline in Bone Biomarkers-Serum Bone-ALP, Serum Osteocalcin, Serum PINP and Serum Type I CTX-1 at Week 144

End point title	Change From Baseline in Bone Biomarkers-Serum Bone-ALP, Serum Osteocalcin, Serum PINP and Serum Type I CTX-1 at Week 144

End point description:

Blood samples were collected to perform evaluation of bone biomarkers which included bone-ALP, Serum Osteocalcin, Serum PINP and Serum Type CTX-1. Adjusted mean is the estimated mean change from Baseline in each arm calculated from a repeated measures model adjusting for: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count (factor), age, sex (factor), race (factor), BMI (factor), smoking status (factor), current vitamin D use (factor), Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Baseline value is defined as the latest pre-dose assessment. Change from Baseline was calculated as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Secondary

End point timeframe:

Baseline (Day 1) and at Week 144

End point values	DTG + 3TC - Double-blind Phase + Open-label Phase	DTG + TDF/FTC - Double-blind Phase + Open-label Phase		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	360[78]	359[79]		
Units: Micrograms per Liter (ug/L)				
arithmetic mean (standard error)				
Bone-ALP, Week 144, n=302, 305	-0.25 (± 0.156)	1.88 (± 0.266)		
Serum Osteocalcin, Week 144, n=300, 304	-1.02 (± 0.280)	2.87 (± 0.412)		
PINP, Week 144, n=299, 300	-0.1 (± 0.94)	9.4 (± 1.39)		
CTX-1, Week 144, n=291, 298	0.0505 (± 0.01154)	0.1868 (± 0.01516)		

Notes:

[78] - Safety Population.

[79] - Safety Population.

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Statistical analysis description:	
Week 144, Bone ALP	
Comparison groups	DTG + 3TC - Double-blind Phase + Open-label Phase v DTG + TDF/FTC - Double-blind Phase + Open-label Phase
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	MMRM
Parameter estimate	Mean difference (net)
Point estimate	-2.13
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.74
upper limit	-1.53

Statistical analysis title	Statistical Analysis 4
Statistical analysis description:	
Week 144, CTX-1	
Comparison groups	DTG + 3TC - Double-blind Phase + Open-label Phase v DTG + TDF/FTC - Double-blind Phase + Open-label Phase
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	MMRM
Parameter estimate	Mean difference (net)
Point estimate	-0.1364

Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.1739
upper limit	-0.0988

Statistical analysis title	Statistical Analysis 3
Statistical analysis description:	
Week 144, Serum PINP	
Comparison groups	DTG + 3TC - Double-blind Phase + Open-label Phase v DTG + TDF/FTC - Double-blind Phase + Open-label Phase
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	MMRM
Parameter estimate	Mean difference (net)
Point estimate	-9.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.8
upper limit	-6.2

Statistical analysis title	Statistical Analysis 2
Statistical analysis description:	
Week 144, Serum Osteocalcin	
Comparison groups	DTG + 3TC - Double-blind Phase + Open-label Phase v DTG + TDF/FTC - Double-blind Phase + Open-label Phase
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	MMRM
Parameter estimate	Mean difference (net)
Point estimate	-3.89
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.87
upper limit	-2.91

Secondary: Change from Baseline in bone biomarker-Serum Vitamin D at Weeks 24, 48

End point title	Change from Baseline in bone biomarker-Serum Vitamin D at

Weeks 24, 48

End point description:

Blood samples were collected to perform evaluation of bone biomarker serum vitamin D. Adjusted mean and standard error is presented. Adjusted mean is the estimated mean change from Baseline at each visit in each arm calculated from a repeated measures model adjusting for: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count (factor), age, sex (factor), race (factor), BMI (factor), smoking status (factor), current Vitamin D use (factor), Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Baseline value is defined as the latest pre-dose assessment. Change from Baseline was calculated as value at the indicated time point minus Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Secondary

End point timeframe:

Baseline and at Weeks 24, 48

End point values	DTG + 3TC	DTG + TDF/FTC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	360[80]	359[81]		
Units: Nanomoles per Liter (nmol/L)				
least squares mean (standard error)				
Serum Vitamin D, Week 24, n=346, 344	11.2 (± 1.08)	15.4 (± 1.33)		
Serum Vitamin D, Week 48, n=336, 335	0.3 (± 0.92)	0.4 (± 1.01)		

Notes:

[80] - Safety Population.

[81] - Safety Population.

Statistical analyses

Statistical analysis title	Statistical Analysis 2

Statistical analysis description:

Week 48

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.96
Method	MMRM
Parameter estimate	Mean difference (net)
Point estimate	-0.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.8
upper limit	2.6

Statistical analysis title	Statistical Analysis 1

Statistical analysis description:

Week 24

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.015
Method	MMRM
Parameter estimate	Mean difference (net)
Point estimate	-4.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.5
upper limit	-0.8

Secondary: Change From Baseline in Bone Biomarker-Serum Vitamin D at Week 96

End point title	Change From Baseline in Bone Biomarker-Serum Vitamin D at Week 96

End point description:

Blood samples were collected to perform evaluation of bone biomarker serum vitamin D. Adjusted mean and standard error is presented. Adjusted mean is the estimated mean change from Baseline at each visit in each arm calculated from a repeated measures model adjusting for: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count (factor), age, sex (factor), race (factor), BMI (factor), smoking status (factor), current Vitamin D use (factor), Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Baseline value is defined as the latest pre-dose assessment. Change from Baseline was calculated as value at the indicated time point minus Baseline value. Only those participants available at the specified time points were analyzed.

End point type	Secondary

End point timeframe:

Baseline and at Week 96

End point values	DTG + 3TC	DTG + TDF/FTC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	312[82]	326[83]		
Units: Nanomoles per Liter (nmol/L)				
arithmetic mean (standard error)	-1.7 (± 1.01)	1.3 (± 1.09)		

Notes:

[82] - Safety Population.

[83] - Safety Population.

Statistical analyses

Statistical analysis title	Statistical Analysis

Statistical analysis description:

Week 96

Comparison groups	DTG + 3TC v DTG + TDF/FTC

Number of subjects included in analysis	638
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.048
Method	MMRM
Parameter estimate	Mean difference (net)
Point estimate	-3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.9
upper limit	0

Secondary: Change From Baseline in Bone Biomarker-Serum Vitamin D at Week 144

End point title	Change From Baseline in Bone Biomarker-Serum Vitamin D at Week 144

End point description:

Blood samples were collected to perform evaluation of bone biomarker serum vitamin D. Adjusted mean and standard error is presented. Adjusted mean is the estimated mean change from Baseline at each visit in each arm calculated from a repeated measures model adjusting for: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count (factor), age, sex (factor), race (factor), BMI (factor), smoking status (factor), current Vitamin D use (factor), Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Baseline value is defined as the latest pre-dose assessment. Change from Baseline was calculated as value at the indicated time point minus Baseline value. Only those participants available at the specified time points were analyzed.

End point type	Secondary

End point timeframe:

Baseline and at Week 144

End point values	DTG + 3TC - Double-blind Phase + Open-label Phase	DTG + TDF/FTC - Double-blind Phase + Open-label Phase		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	303[84]	303[85]		
Units: Nanomoles per Liter (nmol/L)				
arithmetic mean (standard error)	1.1 (± 1.20)	1.4 (± 1.22)		

Notes:

[84] - Safety Population.

[85] - Safety Population.

Statistical analyses

Statistical analysis title	Statistical Analysis

Statistical analysis description:

Week 144

Comparison groups	DTG + 3TC - Double-blind Phase + Open-label Phase v DTG + TDF/FTC - Double-blind Phase + Open-label Phase

Number of subjects included in analysis	606
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.887
Method	MMRM
Parameter estimate	Mean difference (net)
Point estimate	-0.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.6
upper limit	3.1

Secondary: Percentage change from Baseline in fasting lipids-Serum or Plasma Cholesterol, Serum or Plasma High density lipoprotein (HDL) Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides at Weeks 24, 48

End point title	Percentage change from Baseline in fasting lipids-Serum or Plasma Cholesterol, Serum or Plasma High density lipoprotein (HDL) Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides at Weeks 24, 48

End point description:

Blood samples were collected to perform evaluation of fasting lipids which included Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides. Baseline value is defined as the latest pre-dose assessment (Day 1). Percentage change from Baseline was calculated as 100 multiplied by ([post-dose visit value minus Baseline value] divided by Baseline value). Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Secondary

End point timeframe:

Baseline and at Weeks 24, 48

End point values	DTG + 3TC	DTG + TDF/FTC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	360[86]	359[87]		
Units: Percentage change				
arithmetic mean (standard deviation)				
Serum or Plasma Cholesterol, Week 24, n=298, 310	5.0 (± 16.85)	-4.5 (± 15.44)		
Serum or Plasma Cholesterol, Week 48, n=298, 307	9.3 (± 17.10)	-3.3 (± 14.61)		
HDL Cholesterol, Direct, Week 24, n=299, 310	13.9 (± 25.17)	7.2 (± 32.22)		
HDL Cholesterol, Direct, Week 48, n=299, 307	15.3 (± 23.75)	4.0 (± 21.86)		
LDL Cholesterol, Week 24, n=298, 309	3.8 (± 25.85)	-7.8 (± 21.13)		
LDL Cholesterol, Week 48, n=297, 307	10.7 (± 27.54)	-4.1 (± 20.39)		
Triglycerides, Week 24, n=299, 310	7.0 (± 40.45)	0.5 (± 44.01)		
Triglycerides, Week 48, n=299, 307	7.3 (± 46.92)	-0.3 (± 49.22)		

Notes:

[86] - Safety Population.

[87] - Safety Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Fasting Lipids-Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides at Week 96

End point title	Change From Baseline in Fasting Lipids-Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides at Week 96

End point description:

Blood samples were collected to perform evaluation of fasting lipids which included Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides. Baseline value was defined as the latest pre-dose assessment (Day 1). Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Secondary

End point timeframe:

Baseline (Day 1) and at Week 96

End point values	DTG + 3TC	DTG + TDF/FTC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	360[88]	359[89]		
Units: Millimoles per liter				
arithmetic mean (standard error)				
Serum or Plasma Cholesterol, Week 96, n=270, 289	0.345 (± 0.0356)	-0.132 (± 0.0375)		
HDL Cholesterol, Direct, Week 96, n=271, 289	0.185 (± 0.0160)	0.071 (± 0.0136)		
LDL Cholesterol, Week 96, n=270, 289	0.139 (± 0.0308)	-0.160 (± 0.0304)		
Triglycerides, Week 96, n=271, 289	0.105 (± 0.0488)	-0.102 (± 0.0365)		

Notes:

[88] - Safety Population.

[89] - Safety Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Fasting Lipids-Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides at Week 144

End point title	Change From Baseline in Fasting Lipids-Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides at Week 144

End point description:

Blood samples were collected to perform evaluation of fasting lipids which included Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides. Baseline value was defined as the latest pre-dose assessment (Day 1). Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Secondary

End point timeframe:

Baseline (Day 1) and at Week 144

End point values	DTG + 3TC - Double-blind Phase + Open-label Phase	DTG + TDF/FTC - Double-blind Phase + Open-label Phase		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	360[90]	359[91]		
Units: Millimoles per liter				
arithmetic mean (standard error)				
Serum or Plasma Cholesterol, Week 144, n=263, 278	0.360 (± 0.0432)	-0.015 (± 0.0394)		
HDL Cholesterol, Direct, Week 144, n=264, 278	0.180 (± 0.0162)	0.093 (± 0.0136)		
LDL Cholesterol, Week 144, n=263, 278	0.143 (± 0.0357)	-0.085 (± 0.0333)		
Triglycerides, Week 144, n=264, 278	0.078 (± 0.0448)	-0.057 (± 0.0430)		

Notes:

[90] - Safety Population.

[91] - Safety Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage change from Baseline in fasting lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio at Weeks 24, 48

End point title	Percentage change from Baseline in fasting lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio at Weeks 24, 48

End point description:

Blood samples were collected to perform evaluation of fasting lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio. Baseline value is the the latest pre-dose assessment (Day 1). Percentage change from Baseline was calculated as 100 multiplied by ([post-dose visit value minus Baseline value] divided by Baseline value). Lipid last observation carried forwarded (LOCF) data was used such that the last available fasted, on-treatment lipid value prior to the initiation of a lipid-lowering agent was used in place of future observed values. Participants on lipid-lowering agents at Baseline were excluded. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Secondary

End point values	DTG + 3TC	DTG + TDF/FTC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	360[92]	359[93]		
Units: Percentage change				
arithmetic mean (standard deviation)				
Total/HDL Cholesterol Ratio, Week 24, n=298, 310	-4.4 (± 22.53)	-7.5 (± 17.90)		
Total/HDL Cholesterol Ratio, Week 48, n=298, 307	-2.8 (± 17.86)	-4.5 (± 18.25)		

Notes:

[92] - Safety Population.

[93] - Safety Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Fasting Lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio at Week 96

End point title	Change From Baseline in Fasting Lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio at Week 96

End point description:

Blood samples were collected to perform evaluation of fasting lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio. Baseline value is the the latest pre-dose assessment (Day 1). Baseline value was defined as the latest pre-dose assessment (Day 1). Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented. Only those participants available at the specified time points were analyzed.

End point type	Secondary

End point timeframe:

Baseline (Day 1) and at Week 96

End point values	DTG + 3TC	DTG + TDF/FTC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	270[94]	289[95]		
Units: Ratio				
arithmetic mean (standard error)	-0.113 (± 0.1552)	-0.395 (± 0.0473)		

Notes:

[94] - Safety Population.

[95] - Safety Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants with Grade 2 or greater laboratory abnormalities in fasting LDL cholesterol by Weeks 24, 48

End point title	Percentage of participants with Grade 2 or greater laboratory abnormalities in fasting LDL cholesterol by Weeks 24, 48

End point description:

Blood samples were collected to perform evaluation of fasting LDL cholesterol. Any abnormalities were evaluated by the investigator and graded according to DAIDS toxicity scales from Grade 1 to 4 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening). The higher the grade, the more severe the symptoms. Percentage of participants with Grade 2 or greater laboratory abnormalities in fasting LDL cholesterol by Weeks 24 and 48 have been presented. Participants without any post-Baseline fasting LDL cholesterol value prior to Week 48 or those who had Baseline lipids-lowering agents were not included. Lipid Last Observation Carried Forward (LOCF) data was used such that the last available fasted, on-treatment lipid value prior to the initiation of a lipid-lowering agent was used in place of future observed values. Percentage values are rounded-off. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Secondary

End point timeframe:

Weeks 24 and 48

End point values	DTG + 3TC	DTG + TDF/FTC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	360[96]	359[97]		
Units: Percentage of participants				
Week 24, n=313, 320	4	0		
Week 48, n=324, 332	4	2		

Notes:

[96] - Safety Population.

[97] - Safety Population.

Statistical analyses

Statistical analysis title	Statistical Analysis 2

Statistical analysis description:

Week 48

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.037
Method	Fisher exact
Parameter estimate	Mean difference (final values)
Point estimate	2.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.2
upper limit	5.4

	Statistical Analysis 1

Statistical analysis title

Statistical analysis description: Week 24	
Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Fisher exact
Parameter estimate	Mean difference (final values)
Point estimate	3.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.5
upper limit	5.6

Secondary: Change From Baseline in Fasting Lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio at Week 144

End point title	Change From Baseline in Fasting Lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio at Week 144

End point description:

Blood samples were collected to perform evaluation of fasting lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio. Baseline value is the the latest pre-dose assessment (Day 1). Baseline value was defined as the latest pre-dose assessment (Day 1). Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented. Only those participants available at the specified time points were analyzed.

End point type	Secondary

End point timeframe:

Baseline (Day 1) and at Week 144

End point values	DTG + 3TC - Double-blind Phase + Open-label Phase	DTG + TDF/FTC - Double-blind Phase + Open-label Phase		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	263[98]	278[99]		
Units: Ratio				
arithmetic mean (standard error)	-0.245 (± 0.0545)	-0.359 (± 0.0533)		

Notes:

[98] - Safety Population.

[99] - Safety Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With Grade 2 or Greater Laboratory Abnormalities in Fasting LDL Cholesterol by Week 144

End point title	Percentage of Participants With Grade 2 or Greater Laboratory Abnormalities in Fasting LDL Cholesterol by Week 144

End point description:

Blood samples were collected to perform evaluation of fasting LDL cholesterol. Any abnormalities were evaluated by the investigator and graded according to DAIDS toxicity scales from Grade 1 to 4 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening). Percentage of participants with Grade 2 or greater laboratory abnormalities in fasting LDL cholesterol by Week 144 have been presented. Participants without any post-Baseline fasting LDL cholesterol value prior to Week 144 or those who had Baseline lipids-lowering agents were not included. Lipid Last Observation Carried Forward (LOCF) data was used such that the last available fasted, on-treatment lipid value prior to the initiation of a lipid-lowering agent was used in place of future observed values. Percentage values are rounded-off. Only those participants available at the specified time points were analyzed.

End point type	Secondary

End point timeframe:

Week 144

End point values	DTG + 3TC - Double-blind Phase + Open-label Phase	DTG + TDF/FTC - Double-blind Phase + Open-label Phase		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	324[100]	333[101]		
Units: Percentage of participants	6	4		

Notes:

[100] - Safety Population.

[101] - Safety Population.

Statistical analyses

Statistical analysis title	Statistical Analysis

Statistical analysis description:

Week 144

Comparison groups	DTG + 3TC - Double-blind Phase + Open-label Phase v DTG + TDF/FTC - Double-blind Phase + Open-label Phase
Number of subjects included in analysis	657
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.16
Method	Fisher exact
Parameter estimate	Mean difference (final values)
Point estimate	2.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.8
upper limit	6

Secondary: Percentage of Participants With Grade 2 or Greater Laboratory Abnormalities in Fasting LDL Cholesterol by Week 96

End point title	Percentage of Participants With Grade 2 or Greater Laboratory Abnormalities in Fasting LDL Cholesterol by Week 96

End point description:

Blood samples were collected to perform evaluation of fasting LDL cholesterol. Any abnormalities were evaluated by the investigator and graded according to DAIDS toxicity scales from Grade 1 to 4 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening). The higher the grade, the more severe the symptoms. Percentage of participants with Grade 2 or greater laboratory abnormalities in fasting LDL cholesterol by Week 96 have been presented. Participants without any post-Baseline fasting LDL cholesterol value prior to Week 96 or those who had Baseline lipids-lowering agents were not included. Lipid Last Observation Carried Forward (LOCF) data was used such that the last available fasted, on-treatment lipid value prior to the initiation of a lipid-lowering agent was used in place of future observed values. Percentage values are rounded-off. Only those participants available at the specified time points were analyzed.

End point type	Secondary

End point timeframe:

Week 96

End point values	DTG + 3TC	DTG + TDF/FTC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	324[102]	332[103]		
Units: Percentage of participants	6	2		

Notes:

[102] - Safety Population.

[103] - Safety Population.

Statistical analyses

Statistical analysis title	Statistical Analysis

Statistical analysis description:

Week 96

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	656
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.045
Method	Fisher exact
Parameter estimate	Mean difference (final values)
Point estimate	3.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.2
upper limit	6.1

Secondary: Percentage of participants by subgroups (by age, gender, Baseline CD4+ cell count, Baseline HIV-1 RNA, race) with plasma HIV-1 RNA <50 c/mL at Week 24

End point title	Percentage of participants by subgroups (by age, gender,

		Baseline CD4+ cell count, Baseline HIV-1 RNA, race) with plasma HIV-1 RNA <50 c/mL at Week 24

End point description:

Percentage of participants by subgroups (by age, gender, Baseline CD4+ cell count, Baseline HIV-1 RNA, race) with HIV-1 RNA<50 c/mL was obtained using FDA Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. Data was presented by subgroups: age (<35, 35 to <50, >=50 years); gender (males and females), Baseline CD4+ cell count (<=200 cells/mm^3, >200 cells/mm^3 for group-1), Baseline HIV-1 RNA (<=100000, >100000 c/mL) and Race (White, African American/African heritage (H.), Asian other). Percentage values are rounded-off. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Secondary

End point timeframe:

Week 24

End point values	DTG + 3TC	DTG + TDF/FTC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	360[104]	359[105]		
Units: Percentage of participants				
Baseline CD4+ cell count Group-1, <=200,n=32,26	78	92		
Baseline CD4+ cell count Group-1, >200,n=328,333	95	94		
Female, n=54, 46	93	89		
Male, n=306, 313	94	95		
Age, <35,n= 209, 203	93	94		
Age, 35 to <50,n=115, 122	96	94		
Age, >=50, n=36, 34	94	91		
Baseline plasma HIV-1 RNA, <=100000,n=294,282	94	95		
Baseline plasma HIV-1 RNA, >100000,n=66, 77	92	90		
Race, White, n=237,249	95	95		
Race, African American/African H., n=55, 40	89	90		
Race, Asian, n=34, 30	97	90		
Race, Other, n=34, 40	91	93		

Notes:

[104] - ITT-E Population.

[105] - ITT-E Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants by subgroups (by age, gender, Baseline CD4+ cell count Baseline HIV-1 RNA, race) with plasma HIV-1 RNA <50 c/mL at Week 48

End point title	Percentage of participants by subgroups (by age, gender, Baseline CD4+ cell count Baseline HIV-1 RNA, race) with plasma HIV-1 RNA <50 c/mL at Week 48

End point description:

Percentage of participants by subgroups (by age, gender, Baseline CD4+ cell count, Baseline HIV-1

RNA, race) with HIV-1 RNA<50 c/mL was obtained using FDA Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. Data was presented by subgroups: age (<35, 35 to <50, >=50 years); gender (males and females), Baseline CD4+ cell count (<=200 cells/mm^3, >200 cells/mm^3 for group-1), Baseline HIV-1 RNA (<=100000, >100000) and Race (White, African American/African H., Asian and other). Percentage values are rounded-off. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Secondary

End point timeframe:
Week 48

End point values	DTG + 3TC	DTG + TDF/FTC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	360[106]	359[107]		
Units: Percentage of participants				
Baseline CD4+ cell count Group-1, <=200,n=32, 26	78	96		
Baseline CD4+ cell count Group-1, >200,n=328,333	95	94		
Female, n=54, 46	89	87		
Male, n=306, 313	94	95		
Age, <35,n= 209,203	92	94		
Age, 35 to <50,n=115, 122	97	94		
Age, >=50, n=36, 34	89	94		
Baseline plasma HIV-1 RNA, <=100000,n=294,282	92	95		
Baseline plasma HIV-1 RNA, >100000,n=66, 77	97	90		
Race, White, n=237,249	96	96		
Race, African American/African H., n=55, 40	80	88		
Race, Asian, n=34, 30	97	90		
Race, Other, n=34, 40	88	90		

Notes:

[106] - ITT-E Population.

[107] - ITT-E Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants by Subgroups (by Age, Gender, Baseline CD4+ Cell Count Baseline HIV-1 RNA, Race) With Plasma HIV-1 RNA <50 c/mL at Week 96

End point title	Percentage of Participants by Subgroups (by Age, Gender, Baseline CD4+ Cell Count Baseline HIV-1 RNA, Race) With Plasma HIV-1 RNA <50 c/mL at Week 96

End point description:

Percentage of participants by subgroups (by age, gender, Baseline CD4+ cell count, Baseline HIV-1 RNA, race) with HIV-1 RNA<50 c/mL was obtained using FDA Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as

participants who switch their concomitant ART prior to the visit of interest. Data was presented by subgroups: age (<35, 35 to <50, >=50 years); gender (males and females), Baseline CD4+ cell count (<=200 cells/mm^3, >200 cells/mm^3), Baseline HIV-1 RNA (<=100000, >100000) and Race (White, African American/African H., Asian and other). Percentage values are rounded-off. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Secondary

End point timeframe:
Week 96

End point values	DTG + 3TC	DTG + TDF/FTC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	360[108]	359[109]		
Units: Percentage of participants				
Baseline CD4+ cell count, <=200,n=32, 26	72	85		
Baseline CD4+ cell count, >200,n=328,333	89	90		
Female, n=54, 46	81	85		
Male, n=306, 313	89	90		
Age, <35,n= 209, 203	88	91		
Age, 35 to <50,n=115, 122	90	89		
Age, >=50, n=36, 34	83	88		
Baseline plasma HIV-1 RNA, <=100000,n=294, 282	88	91		
Baseline plasma HIV-1 RNA, >100000,n=66, 77	86	84		
Race, White, n=240,252	92	91		
Race, African American/African H., n=51, 35	69	86		
Race, Asian, n=34, 30	88	90		
Race, Other, n=35, 42	89	83		

Notes:

[108] - ITT-E Population.

[109] - ITT-E Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants by Subgroups (by Age, Gender, Baseline CD4+ Cell Count Baseline HIV-1 RNA, Race) With Plasma HIV-1 RNA <50 c/mL at Week 144

End point title	Percentage of Participants by Subgroups (by Age, Gender, Baseline CD4+ Cell Count Baseline HIV-1 RNA, Race) With Plasma HIV-1 RNA <50 c/mL at Week 144

End point description:

Percentage of participants by subgroups (by age, gender, Baseline CD4+ cell count, Baseline HIV-1 RNA, race) with HIV-1 RNA<50 c/mL was obtained using FDA Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. Data was presented by subgroups: age (<35, 35 to <50, >=50 years); gender (males and females), Baseline CD4+ cell count (<=200 cells/mm^3, >200 cells/mm^3), Baseline HIV-1 RNA (<=100000, >100000) and Race (White,

African American/African H., Asian and other). Percentage values are rounded-off. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Secondary
End point timeframe:	
Week 144	

End point values	DTG + 3TC - Double-blind Phase + Open-label Phase	DTG + TDF/FTC - Double-blind Phase + Open-label Phase		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	360[110]	359[111]		
Units: Percentage of participants				
Baseline CD4+ cell count, <=200,n=32, 26	75	69		
Baseline CD4+ cell count, >200,n=328,333	85	86		
Female, n=54, 46	78	83		
Male, n=306, 313	85	85		
Age, <35,n= 209, 203	83	83		
Age, 35 to <50,n=115, 122	86	85		
Age, >=50, n=36, 34	83	88		
Baseline plasma HIV-1 RNA, <=100000,n=294, 282	84	85		
Baseline plasma HIV-1 RNA, >100000,n=66, 77	86	81		
Race, White, n=240,252	88	87		
Race, African American/African H., n=51, 35	65	74		
Race, Asian, n=34, 30	85	83		
Race, Other, n=35, 42	89	79		

Notes:

[110] - ITT-E Population.

[111] - ITT-E Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Changes from Baseline in CD4+ cell counts at Week 24 by subgroups

End point title	Changes from Baseline in CD4+ cell counts at Week 24 by subgroups

End point description:

CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, number of these cells declines. It was evaluated by flow cytometry. Baseline value is latest pre-dose assessment (Day 1). Change from Baseline was defined as value at indicated time point minus Baseline value. Adjusted mean and standard error is presented for subgroups (Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, Age group, Gender and race). For each subgroup, adjusted mean is the estimated mean change from Baseline in each arm calculated from ANCOVA model adjusting for the following covariates/factors: treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, subgroup, and treatment and relevant subgroup interaction. For CD4+ cell count subgroup, Baseline CD4+ cell count group is included as a factor only. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Secondary
End point timeframe:	
Baseline (Day 1) and Week 24	

End point values	DTG + 3TC	DTG + TDF/FTC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	360[112]	359[113]		
Units: Cells/mm^3				
arithmetic mean (standard error)				
Baseline plasma HIV-1 RNA,<=100000, n=283,273	186.01 (± 9.948)	148.21 (± 10.134)		
Baseline plasma HIV-1 RNA,>100000, n=66,72	193.90 (± 20.811)	220.71 (± 19.814)		
Baseline CD4+ cell count,<=200, n=29, 26	167.95 (± 31.308)	106.23 (± 32.990)		
Baseline CD4+ cell count,>200, n=320, 319	189.91 (± 9.362)	167.35 (± 9.362)		
Age group, <35,n= 201, 193	190.12 (± 11.829)	151.13 (± 12.050)		
Age group-1, 35 to <50, n=113, 119	180.50 (± 15.733)	190.40 (± 15.404)		
Age group-1, >=50, n=32, 32	198.74 (± 28.411)	133.21 (± 29.120)		
Female, n=52, 42	213.58 (± 23.225)	153.92 (± 25.910)		
Male, n=297, 303	183.41 (± 9.719)	164.18 (± 9.631)		
Race group, White, n=233, 240	182.20 (± 10.987)	168.30 (± 10.846)		
Race group, African Am/African H., n=51, 39	214.17 (± 23.472)	145.44 (± 26.841)		
Race group, Asian, n=33, 28	154.14 (± 29.401)	141.22 (± 31.663)		
Race group, Other, n=32, 38	222.24 (± 29.643)	163.05 (± 27.293)		

Notes:

[112] - ITT-E Population.

[113] - ITT-E Population.

Statistical analyses

Statistical analysis title	Statistical Analysis 4
Statistical analysis description:	
Baseline CD4+ cell count,>200. Following covariates were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, and treatment and Baseline CD4+ cell count interaction.	
Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	22.57

Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.42
upper limit	48.55

Statistical analysis title	Statistical Analysis 3

Statistical analysis description:

Baseline CD4+ cell count,<=200. Following covariates were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, and treatment and Baseline CD4+ cell count interaction.

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	61.72
Confidence interval	
level	95 %
sides	2-sided
lower limit	-26.94
upper limit	150.39

Statistical analysis title	Statistical Analysis 2

Statistical analysis description:

Baseline plasma HIV-1 RNA,>100000. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, Baseline plasma HIV-1 RNA, and treatment and Baseline plasma HIV-1 RNA interaction.

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	-26.81
Confidence interval	
level	95 %
sides	2-sided
lower limit	-82.72
upper limit	29.1

Statistical analysis title	Statistical Analysis 1

Statistical analysis description:

Baseline plasma HIV-1 RNA,<=100000. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, Baseline plasma HIV-1 RNA, and treatment and relevant Baseline plasma HIV-1 RNA interaction.

Comparison groups	DTG + 3TC v DTG + TDF/FTC

Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	37.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	9.98
upper limit	65.62

Statistical analysis title	Statistical Analysis 9

Statistical analysis description:

Male. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, gender, and treatment and gender interaction.

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	19.23
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.65
upper limit	46.1

Statistical analysis title	Statistical Analysis 10

Statistical analysis description:

Race group-white. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, race, and treatment and race interaction.

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	13.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.35
upper limit	44.15

Statistical analysis title	Statistical Analysis 11

Statistical analysis description:

Race group-African Am/African H. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, race, and treatment and race interaction.

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	68.74
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.24
upper limit	138.72

Statistical analysis title	Statistical Analysis 12

Statistical analysis description:

Race group-Asian. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, race, and treatment and race interaction.

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	12.93
Confidence interval	
level	95 %
sides	2-sided
lower limit	-71.9
upper limit	97.75

Statistical analysis title	Statistical Analysis 8

Statistical analysis description:

Female. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, gender, and treatment and gender interaction.

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	59.66
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.62
upper limit	127.94

Statistical analysis title	Statistical Analysis 13
Statistical analysis description:	
Race group-Other. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, race, and treatment and race interaction.	
Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	59.19
Confidence interval	
level	95 %
sides	2-sided
lower limit	-19.73
upper limit	138.11

Statistical analysis title	Statistical Analysis 6
Statistical analysis description:	
Age Group,35 to <50. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, age, and treatment and age interaction.	
Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	-9.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-53.1
upper limit	33.3

Statistical analysis title	Statistical Analysis 5
Statistical analysis description:	
Age Group,<35. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, age, and treatment and age interaction.	
Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	38.99

Confidence interval	
level	95 %
sides	2-sided
lower limit	5.88
upper limit	72.09

Statistical analysis title	Statistical Analysis 7

Statistical analysis description:

Age Group,>=50. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, age, and treatment and age interaction.

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	65.53
Confidence interval	
level	95 %
sides	2-sided
lower limit	-14.43
upper limit	145.5

Secondary: Changes from Baseline in CD4+ cell counts at Week 48 by subgroups

End point title	Changes from Baseline in CD4+ cell counts at Week 48 by subgroups

End point description:

CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. It was evaluated by flow cytometry. Baseline value is the latest pre-dose assessment (Day 1). Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented for subgroups (Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, Age group, Gender and race). For each subgroup, adjusted mean is the estimated mean change from Baseline in each arm calculated from Analysis of Covariance (ANCOVA) model adjusting for the following covariates/factors: treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, subgroup, and treatment and relevant subgroup interaction. For CD4+ cell count subgroup, Baseline CD4+ cell count group is included as a factor only. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Secondary

End point timeframe:

Baseline (Day 1) and Week 48

End point values	DTG + 3TC	DTG + TDF/FTC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	360[114]	359[115]		
Units: Cells/mm^3				
least squares mean (standard error)				

Baseline plasma HIV-1 RNA,<=100000, n=273,271	215.6 (± 10.67)	208.7 (± 10.71)		
Baseline plasma HIV-1 RNA,>100000, n=64,69	261.8 (± 22.27)	248.7 (± 21.30)		
Baseline CD4+ cell count,<=200, n=28, 25	210.9 (± 33.42)	153.2 (± 35.29)		
Baseline CD4+ cell count,>200, n=309, 315	225.8 (± 10.00)	221.7 (± 9.89)		
Age group-1, <35,n= 193, 191	234.2 (± 12.67)	201.7 (± 12.72)		
Age group-1, 35 to <50, n=112, 117	212.7 (± 16.59)	244.2 (± 16.31)		
Age group-1, >=50, n=32, 32	209.1 (± 31.20)	203.9 (± 31.06)		
Age group-2, <50,n= 305, 308	226.4 (± 10.09)	217.8 (± 10.03)		
Age group-2, >=50, n= 32, 32	208.5 (± 31.27)	204.1 (± 31.14)		
Female, n=48, 41	236.2 (± 25.35)	263.6 (± 27.50)		
Male, n=289, 299	222.8 (± 10.33)	210.0 (± 10.17)		
Race group, White, n=227, 241	223.3 (± 11.70)	214.2 (± 11.38)		
Race group, African Am/African H., n=45, 36	214.0 (± 26.25)	233.7 (± 29.39)		
Race group, Asian, n=33, 27	205.0 (± 30.92)	189.3 (± 33.90)		
Race group, Other, n=32, 36	270.2 (± 31.16)	235.3 (± 29.47)		

Notes:

[114] - ITT-E Population.

[115] - ITT-E Population.

Statistical analyses

Statistical analysis title	Statistical Analysis 4
Statistical analysis description:	
Baseline CD4+ cell count,>200. Following covariates were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, and treatment and Baseline CD4+ cell count interaction.	
Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	4.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-23.5
upper limit	31.7

Statistical analysis title	Statistical Analysis 3
Statistical analysis description:	
Baseline CD4+ cell count,<=200. Following covariates were adjusted: Treatment, Baseline plasma HIV-	

1 RNA (factor), Baseline CD4+ cell count, and treatment and Baseline CD4+ cell count interaction.

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	57.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-37.2
upper limit	152.5

Statistical analysis title	Statistical Analysis 2

Statistical analysis description:

Baseline plasma HIV-1 RNA,>100000. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, Baseline plasma HIV-1 RNA, and treatment and Baseline plasma HIV-1 RNA interaction.

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	13.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-46.8
upper limit	73.2

Statistical analysis title	Statistical Analysis 1

Statistical analysis description:

Baseline plasma HIV-1 RNA,<=100000. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, Baseline plasma HIV-1 RNA, and treatment and relevant Baseline plasma HIV-1 RNA interaction.

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	6.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-22.7
upper limit	36.6

Statistical analysis title	Statistical Analysis 9

Statistical analysis description:

Male. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, gender, and treatment and gender interaction.

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	12.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-15.7
upper limit	41.2

Statistical analysis title	Statistical Analysis 10

Statistical analysis description:

Race group-white. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, race, and treatment and race interaction.

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	9.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-22.9
upper limit	41.1

Statistical analysis title	Statistical Analysis 11

Statistical analysis description:

Race group-African Am/African H. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, race, and treatment and race interaction.

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	-19.8

Confidence interval	
level	95 %
sides	2-sided
lower limit	-97.1
upper limit	57.6

Statistical analysis title	Statistical Analysis 12

Statistical analysis description:

Race group-Asian. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, race, and treatment and race interaction.

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	15.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-74.4
upper limit	105.9

Statistical analysis title	Statistical Analysis 8

Statistical analysis description:

Female. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, gender, and treatment and gender interaction.

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	-27.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-100.8
upper limit	46.1

Statistical analysis title	Statistical Analysis 13

Statistical analysis description:

Race group-Other. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, race, and treatment and race interaction.

Comparison groups	DTG + 3TC v DTG + TDF/FTC

Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	35
Confidence interval	
level	95 %
sides	2-sided
lower limit	-49
upper limit	119

Statistical analysis title	Statistical Analysis 6

Statistical analysis description:

Age Group-1,35 to <50. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, age, and treatment and age interaction.

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	-31.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-77.1
upper limit	14.2

Statistical analysis title	Statistical Analysis 5

Statistical analysis description:

Age Group-1,<35. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, age, and treatment and age interaction.

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	32.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.7
upper limit	67.7

Statistical analysis title	Statistical Analysis 7

Statistical analysis description:

Age Group-1,>=50. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, age, and treatment and age interaction.

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	5.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-81.4
upper limit	91.8

Secondary: Changes From Baseline in CD4+ Cell Counts at Week 96 by Subgroups

End point title	Changes From Baseline in CD4+ Cell Counts at Week 96 by Subgroups

End point description:

CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. It was evaluated by flow cytometry. Baseline value is the latest pre-dose assessment (Day 1). Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented for subgroups (Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, Age group, Gender and race). For each subgroup, adjusted mean is the estimated mean change from Baseline in each arm calculated from ANCOVA model adjusting for the following covariates/factors: treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, subgroup, and treatment and relevant subgroup interaction. For CD4+ cell count subgroup, Baseline CD4+ cell count group is included as a factor only. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Secondary

End point timeframe:

Baseline (Day 1) and Week 96

End point values	DTG + 3TC	DTG + TDF/FTC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	360[116]	359[117]		
Units: Cells/mm^3				
arithmetic mean (standard error)				
Baseline plasma HIV-1 RNA,<=100000, n=259,260	257.9 (± 12.47)	257.5 (± 12.45)		
Baseline plasma HIV-1 RNA,>100000, n=59,67	312.1 (± 26.37)	297.4 (± 24.59)		
Baseline CD4+ cell count,<=200, n=25, 23	229.4 (± 40.41)	202.9 (± 42.00)		
Baseline CD4+ cell count,>200, n=293, 304	272.3 (± 11.73)	269.4 (± 11.50)		
Age group-1, <35,n= 186, 187	266.0 (± 14.74)	257.7 (± 14.68)		
Age group-1, 35 to <50, n=101, 110	273.6 (± 19.95)	286.8 (± 19.22)		

Age group-1, >=50, n=31, 30	265.8 (± 36.14)	233.1 (± 36.61)		
Female, n=44, 40	312.7 (± 30.12)	307.6 (± 31.67)		
Male, n=274, 287	261.4 (± 12.07)	259.3 (± 11.81)		
Race group, White, n=221, 234	272.1 (± 13.49)	258.3 (± 13.14)		
Race group, African Am/African H., n=35, 30	246.3 (± 33.90)	303.7 (± 36.61)		
Race group, Asian, n=31, 27	224.0 (± 36.31)	264.0 (± 38.57)		
Race group, Other, n=31, 36	312.0 (± 36.01)	278.9 (± 33.56)		

Notes:

[116] - ITT-E Population.

[117] - ITT-E Population.

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Statistical analysis description:	
Baseline plasma HIV-1 RNA,<=100000. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, Baseline plasma HIV-1 RNA, and treatment and relevant Baseline plasma HIV-1 RNA interaction.	
Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	0.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-34.1
upper limit	35

Statistical analysis title	Statistical Analysis 2
Statistical analysis description:	
Baseline plasma HIV-1 RNA,>100000. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, Baseline plasma HIV-1 RNA, and treatment and Baseline plasma HIV-1 RNA interaction.	
Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	14.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-55.6
upper limit	84.9

Statistical analysis title	Statistical Analysis 3

Statistical analysis description:

Baseline CD4+ cell count,<=200. Following covariates were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, and treatment and Baseline CD4+ cell count interaction.

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	26.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-87.3
upper limit	140.3

Statistical analysis title	Statistical Analysis 4

Statistical analysis description:

Baseline CD4+ cell count,>200. Following covariates were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, and treatment and Baseline CD4+ cell count interaction.

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	2.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-29.4
upper limit	35.1

Statistical analysis title	Statistical Analysis 5

Statistical analysis description:

Age Group,<35. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, age, and treatment and age interaction.

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	8.3

Confidence interval	
level	95 %
sides	2-sided
lower limit	-32.5
upper limit	49.1

Statistical analysis title	Statistical Analysis 6

Statistical analysis description:

Age Group,35 to <50. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, age, and treatment and age interaction.

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	-13.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-67.6
upper limit	41.1

Statistical analysis title	Statistical Analysis 7

Statistical analysis description:

Age Group,>=50. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, age, and treatment and age interaction.

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	32.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-68.5
upper limit	133.9

Statistical analysis title	Statistical Analysis 8

Statistical analysis description:

Female. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, gender, and treatment and gender interaction.

Comparison groups	DTG + 3TC v DTG + TDF/FTC

Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	5.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-80.7
upper limit	90.8

Statistical analysis title	Statistical Analysis 9

Statistical analysis description:

Male. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, gender, and treatment and gender interaction.

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	2.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-31.1
upper limit	35.3

Statistical analysis title	Statistical Analysis 10

Statistical analysis description:

Race group-white. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, race, and treatment and race interaction.

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	13.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-23.2
upper limit	50.6

Statistical analysis title	Statistical Analysis 11

Statistical analysis description:

Race group-African Am/African H. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, race, and treatment and race interaction.

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	-57.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-155.3
upper limit	40.4

Statistical analysis title	Statistical Analysis 12

Statistical analysis description:

Race group-Asian. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, race, and treatment and race interaction.

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	-40.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-144.2
upper limit	64

Statistical analysis title	Statistical Analysis 13

Statistical analysis description:

Race group-Other. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, race, and treatment and race interaction.

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	33.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-63.3
upper limit	129.6

Secondary: Changes From Baseline in CD4+ Cell Counts at Week 144 by Subgroups

End point title	Changes From Baseline in CD4+ Cell Counts at Week 144 by Subgroups

End point description:

CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. It was evaluated by flow cytometry. Baseline value is the latest pre-dose assessment (Day 1). Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented for subgroups (Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, Age group, Gender and race). For each subgroup, adjusted mean is the estimated mean change from Baseline in each arm calculated from ANCOVA model adjusting for the following covariates/factors: treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, subgroup, and treatment and relevant subgroup interaction. For CD4+ cell count subgroup, Baseline CD4+ cell count group is included as a factor only. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Secondary

End point timeframe:

Baseline (Day 1) and Week 144

End point values	DTG + 3TC - Double-blind Phase + Open-label Phase	DTG + TDF/FTC - Double-blind Phase + Open-label Phase		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	360[118]	359[119]		
Units: Cells/mm^3				
arithmetic mean (standard error)				
Baseline plasma HIV-1 RNA,<=100000, n=241,234	286.8 (± 14.36)	277.8 (± 14.58)		
Baseline plasma HIV-1 RNA,>100000, n=55,58	338.2 (± 30.34)	354.7 (± 29.35)		
Baseline CD4+ cell count,<=200, n=25, 19	264.8 (± 44.91)	208.9 (± 51.25)		
Baseline CD4+ cell count,>200, n=271, 273	300.3 (± 13.54)	297.9 (± 13.48)		
Age group, <35,n=171, 159	302.9 (± 17.05)	277.1 (± 17.65)		
Age group-1, 35 to <50, n=95, 103	292.8 (± 22.82)	329.2 (± 22.02)		
Age group-1, >=50, n=30, 30	274.1 (± 40.71)	250.0 (± 40.60)		
Female, n=40, 37	355.0 (± 34.93)	381.8 (± 36.37)		
Male, n=256, 255	287.7 (± 13.81)	279.6 (± 13.85)		
Race group, White, n=202, 211	300.0 (± 15.61)	296.5 (± 15.29)		
Race group, African Am/African H., n=34, 24	256.4 (± 38.04)	377.6 (± 45.25)		
Race group, Asian, n=29, 25	258.5 (± 41.57)	245.4 (± 44.36)		
Race group, Other, n=31, 32	355.0 (± 39.84)	240.7 (± 39.35)		

Statistical analyses

Statistical analysis title	Statistical Analysis 4
Statistical analysis description:	
Baseline CD4+ cell count,>200. Following covariates were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, and treatment and Baseline CD4+ cell count interaction.	
Comparison groups	DTG + 3TC - Double-blind Phase + Open-label Phase v DTG + TDF/FTC - Double-blind Phase + Open-label Phase
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	2.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-35.2
upper limit	39.9

Statistical analysis title	Statistical Analysis 3
Statistical analysis description:	
Baseline CD4+ cell count,<=200. Following covariates were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, and treatment and Baseline CD4+ cell count interaction.	
Comparison groups	DTG + 3TC - Double-blind Phase + Open-label Phase v DTG + TDF/FTC - Double-blind Phase + Open-label Phase
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	56
Confidence interval	
level	95 %
sides	2-sided
lower limit	-77.2
upper limit	189.1

Statistical analysis title	Statistical Analysis 2
Statistical analysis description:	
Baseline plasma HIV-1 RNA,>100000. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, Baseline plasma HIV-1 RNA, and treatment and Baseline plasma HIV-1 RNA interaction.	
Comparison groups	DTG + 3TC - Double-blind Phase + Open-label Phase v DTG +

	TDF/FTC - Double-blind Phase + Open-label Phase
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	-16.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-98.9
upper limit	65.8

Statistical analysis title	Statistical Analysis 1

Statistical analysis description:

Baseline plasma HIV-1 RNA,<=100000. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, Baseline plasma HIV-1 RNA, and treatment and relevant Baseline plasma HIV-1 RNA interaction.

Comparison groups	DTG + 3TC - Double-blind Phase + Open-label Phase v DTG + TDF/FTC - Double-blind Phase + Open-label Phase
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	9.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-31.1
upper limit	49.2

Statistical analysis title	Statistical Analysis 9

Statistical analysis description:

Male. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, gender, and treatment and gender interaction.

Comparison groups	DTG + 3TC - Double-blind Phase + Open-label Phase v DTG + TDF/FTC - Double-blind Phase + Open-label Phase
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	8.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-30.3
upper limit	46.5

Statistical analysis title	Statistical Analysis 10

Statistical analysis description:

Race group-white. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, race, and treatment and race interaction.

Comparison groups	DTG + 3TC - Double-blind Phase + Open-label Phase v DTG + TDF/FTC - Double-blind Phase + Open-label Phase
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	3.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-39.4
upper limit	46.3

Statistical analysis title	Statistical Analysis 11

Statistical analysis description:

Race group-African Am/African H. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, race, and treatment and race interaction.

Comparison groups	DTG + 3TC - Double-blind Phase + Open-label Phase v DTG + TDF/FTC - Double-blind Phase + Open-label Phase
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	-121.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-237.2
upper limit	-5.1

Statistical analysis title	Statistical Analysis 12

Statistical analysis description:

Race group-Asian. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, race, and treatment and race interaction.

Comparison groups	DTG + 3TC - Double-blind Phase + Open-label Phase v DTG + TDF/FTC - Double-blind Phase + Open-label Phase

Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	13.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-106.4
upper limit	132.6

Statistical analysis title	Statistical Analysis 8
Statistical analysis description:	
Female. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, gender, and treatment and gender interaction.	
Comparison groups	DTG + 3TC - Double-blind Phase + Open-label Phase v DTG + TDF/FTC - Double-blind Phase + Open-label Phase
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	-26.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-125.9
upper limit	72.2

Statistical analysis title	Statistical Analysis 13
Statistical analysis description:	
Race group-Other. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, race, and treatment and race interaction.	
Comparison groups	DTG + 3TC - Double-blind Phase + Open-label Phase v DTG + TDF/FTC - Double-blind Phase + Open-label Phase
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	114.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	4.6
upper limit	224

Statistical analysis title	Statistical Analysis 6
Statistical analysis description:	
Age Group,35 to <50. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, age, and treatment and age interaction.	
Comparison groups	DTG + 3TC - Double-blind Phase + Open-label Phase v DTG + TDF/FTC - Double-blind Phase + Open-label Phase
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	-36.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-98.6
upper limit	25.8

Statistical analysis title	Statistical Analysis 5
Statistical analysis description:	
Age Group,<35. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, age, and treatment and age interaction.	
Comparison groups	DTG + 3TC - Double-blind Phase + Open-label Phase v DTG + TDF/FTC - Double-blind Phase + Open-label Phase
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	25.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-22.3
upper limit	74

Statistical analysis title	Statistical Analysis 7
Statistical analysis description:	
Age Group,>=50. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, age, and treatment and age interaction.	
Comparison groups	DTG + 3TC - Double-blind Phase + Open-label Phase v DTG + TDF/FTC - Double-blind Phase + Open-label Phase
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	24.1

Confidence interval	
level	95 %
sides	2-sided
lower limit	-89
upper limit	137.2

Secondary: Change from Baseline in European Quality of life [EuroQoL] – 5 Dimensions – 5 Levels (EQ-5D-5L) utility score at Weeks 4, 24, 48

End point title	Change from Baseline in European Quality of life [EuroQoL] – 5 Dimensions – 5 Levels (EQ-5D-5L) utility score at Weeks 4, 24, 48

End point description:

EQ-5D-5L questionnaire provides profile of participant function and global health state rating. Five-item measure has 1 question assessing each of 5 dimensions: mobility,self-care,usual activities,pain/discomfort and anxiety/depression and 5 levels for each dimension including 1=no problems,2=slight problems,3=moderate problems,4=severe problems,5=extreme problems. The health state is defined by combining the levels of answers from each of the 5 questions. Each health state is referred to in terms of a 5 digit code. Health state 5 digit code is translated into utility score, which is valued up to 1 (perfect health) with lower values meaning worse state. EQ-5D-5L utility score ranges from -0.281 to 1. Higher scores indicate better health. MMRM was run on LOCF dataset. Baseline was the latest pre-dose assessment and change from Baseline=post-dose value minus Baseline value. Only those participants available at specified time points were analyzed(represented by n=X in category

End point type	Secondary

End point timeframe:

Baseline (Day 1) and Weeks 4, 24, 48

End point values	DTG + 3TC	DTG + TDF/FTC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	360[120]	359[121]		
Units: Scores on a scale				
least squares mean (standard error)				
Week 4, n=359, 355	0.0111 (± 0.00326)	0.0130 (± 0.00510)		
Week 24, n=360, 358	0.0207 (± 0.00310)	0.0203 (± 0.00347)		
Week 48, n=360, 358	0.0189 (± 0.00362)	0.0208 (± 0.00342)		

Notes:

[120] - ITT-E Population.

[121] - ITT-E Population.

Statistical analyses

Statistical analysis title	Statistical Analysis 1

Statistical analysis description:

Week 4. Covariates adjusted: Treatment, Baseline plasma HIV-1 RNA , Baseline CD4+ cell count , and Baseline EQ-5D utility, treatment*visit and Baseline EQ-5D utility*visit as factors and covariate, with visit as the repeated factor.

Comparison groups	DTG + 3TC v DTG + TDF/FTC

Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.759
Method	MMRM
Parameter estimate	Mean difference (net)
Point estimate	-0.0019
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.0137
upper limit	0.01

Statistical analysis title	Statistical Analysis 3

Statistical analysis description:

Week 48. Covariates adjusted: Treatment, Baseline plasma HIV-1 RNA , Baseline CD4+ cell count , and Baseline EQ-5D utility, treatment*visit and Baseline EQ-5D utility*visit as factors and covariate, with visit as the repeated factor.

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.703
Method	MMRM
Parameter estimate	Mean difference (net)
Point estimate	-0.0019
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.0117
upper limit	0.0079

Statistical analysis title	Statistical Analysis 2

Statistical analysis description:

Week 24. Covariates adjusted: Treatment, Baseline plasma HIV-1 RNA , Baseline CD4+ cell count , and Baseline EQ-5D utility, treatment*visit and Baseline EQ-5D utility*visit as factors and covariate, with visit as the repeated factor.

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.943
Method	MMRM
Parameter estimate	Mean difference (net)
Point estimate	0.0003

Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.0088
upper limit	0.0095

Secondary: Change From Baseline in EQ-5D-5L Utility Score at Week 96

End point title	Change From Baseline in EQ-5D-5L Utility Score at Week 96

End point description:

EQ-5D-5L questionnaire provides profile of participant function and global health state rating. Five-item measure has 1 question assessing each of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression and 5 levels for each dimension including 1=no problems,2=slight problems,3=moderate problems,4=severe problems, 5=extreme problems. Health state is defined by combining levels of answers from each of 5 questions. Each health state is referred to in terms of a 5 digit code. Health state 5 digit code is translated into utility score, which is valued up to 1 (perfect health) with lower values meaning worse state. EQ-5D-5L utility score ranges from -0.281 to 1. Higher scores indicate better health. MMRM was run on LOCF dataset. Baseline was the latest pre-dose assessment and change from Baseline=post-dose value minus Baseline value. Adjusted mean and standard error is presented. Only those participants available at the specified time points were analyzed.

End point type	Secondary

End point timeframe:

Baseline (Day 1) and Week 96

End point values	DTG + 3TC	DTG + TDF/FTC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	360[122]	358[123]		
Units: Scores on a scale				
arithmetic mean (standard error)	0.0168 (± 0.00339)	0.0171 (± 0.00424)		

Notes:

[122] - ITT-E Population.

[123] - ITT-E Population.

Statistical analyses

Statistical analysis title	Subject Analysis

Statistical analysis description:

Week 96. Covariates adjusted: Treatment, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, and Baseline EQ-5D utility, treatment*visit and Baseline EQ-5D utility*visit as factors and covariate, with visit as the repeated factor.

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	718
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.957
Method	MMRM
Parameter estimate	Mean difference (net)
Point estimate	-0.0003

Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.011
upper limit	0.0104

Secondary: Change From Baseline in EQ-5D-5L Utility Score at Week 144

End point title	Change From Baseline in EQ-5D-5L Utility Score at Week 144

End point description:

EQ-5D-5L questionnaire provides a profile of participant function and a global health state rating. Five-item measure has 1 question assessing each of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems,5=extreme problems. Health state is defined by combining levels of answers from each of 5 questions. Each health state is referred to in terms of a 5 digit code. Health state 5digit code is translated into utility score, which is valued up to 1 (perfect health) with lower values meaning worse state. EQ-5D-5L utility score ranges from -0.281 to 1. Higher scores indicate better health. MMRM was run on LOCF dataset. Baseline was latest pre-dose assessment and change from Baseline=post-dose value minus Baseline value.Adjusted mean and standard error is presented. Only those participants available at specified time points were analyzed.

End point type	Secondary

End point timeframe:

Baseline (Day 1) and Week 144

End point values	DTG + 3TC - Double-blind Phase + Open-label Phase	DTG + TDF/FTC - Double-blind Phase + Open-label Phase		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	360[124]	358[125]		
Units: Scores on a scale				
arithmetic mean (standard error)	0.0210 (± 0.00346)	0.0131 (± 0.00441)		

Notes:

[124] - ITT-E Population.

[125] - ITT-E Population.

Statistical analyses

Statistical analysis title	Subject Analysis

Statistical analysis description:

Week 144. Covariates adjusted: Treatment, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, and Baseline EQ-5D utility, treatment*visit and Baseline EQ-5D utility*visit as factors and covariate, with visit as the repeated factor.

Comparison groups	DTG + 3TC - Double-blind Phase + Open-label Phase v DTG + TDF/FTC - Double-blind Phase + Open-label Phase

Number of subjects included in analysis	718
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.162
Method	MMRM
Parameter estimate	Mean difference (net)
Point estimate	0.0079
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.0032
upper limit	0.0189

Secondary: Change From Baseline in EuroQol - 5 Dimensions - 5 Levels (EQ-5D-5L) Thermometer Scores at Weeks 4, 24, 48

End point title	Change From Baseline in EuroQol - 5 Dimensions - 5 Levels (EQ-5D-5L) Thermometer Scores at Weeks 4, 24, 48

End point description:

EQ-5D-5L questionnaire provided a profile of participant function and a global health state rating. The five-item measure has one question assessing each of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. EQ-5D-5L included EQ visual Analogue scale (EQ VAS) 'Thermometer' which provided Self-rated current health status. Score ranges from 0 (worst imaginable health state) to 100 (best imaginable health state). MMRM was run on the LOCF dataset, using the observed margins (OM) option. Baseline was the latest pre-dose assessment value and change from Baseline=post-dose value minus Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Secondary

End point timeframe:

Baseline (Day 1) and Weeks 4, 24, 48

End point values	DTG + 3TC	DTG + TDF/FTC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	360[126]	359[127]		
Units: Scores on a scale				
least squares mean (standard error)				
Week 4, n=358, 355	1.8 (± 0.50)	3.1 (± 0.41)		
Week 24, n=359, 358	3.9 (± 0.43)	4.5 (± 0.48)		
Week 48, n=359, 358	4.0 (± 0.43)	4.6 (± 0.48)		

Notes:

[126] - ITT-E Population.

[127] - ITT-E Population.

Statistical analyses

Statistical analysis title	Subject Analysis 1

Statistical analysis description:

Week 4. Covariates adjusted: Treatment, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count and

Baseline EQ-5D utility, treatment*visit and Baseline EQ-5D utility*visit as factors and covariate, with visit as the repeated factor.

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.045
Method	MMRM
Parameter estimate	Mean difference (net)
Point estimate	-1.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.6
upper limit	0

Statistical analysis title	Subject Analysis 3

Statistical analysis description:

Week 48. Covariates adjusted: Treatment, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, and Baseline EQ-5D utility, treatment*visit and Baseline EQ-5D utility*visit as factors and covariate, with visit as the repeated factor.

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.328
Method	MMRM
Parameter estimate	Mean difference (net)
Point estimate	-0.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.9
upper limit	0.6

Statistical analysis title	Subject Analysis 2

Statistical analysis description:

Week 24. Covariates adjusted: Treatment, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count and Baseline EQ-5D utility, treatment*visit and Baseline EQ-5D utility*visit as factors and covariate, with visit as the repeated factor.

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	719
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.358
Method	MMRM
Parameter estimate	Mean difference (net)
Point estimate	-0.6

Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.9
upper limit	0.7

Secondary: Change From Baseline in EQ-5D-5L Thermometer Scores at Week 96

End point title	Change From Baseline in EQ-5D-5L Thermometer Scores at Week 96

End point description:

EQ-5D-5L questionnaire provided a profile of participant function and a global health state rating. The five-item measure has one question assessing each of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. EQ-5D-5L included EQ visual Analogue scale (EQ VAS) 'Thermometer' which provided Self-rated current health status. Score ranges from 0 (worst imaginable health state) to 100 (best imaginable health state). MMRM was run on the LOCF dataset, using the observed margins (OM) option. Baseline was the latest pre-dose assessment value and change from Baseline=post-dose value minus Baseline value. Adjusted mean and standard error is presented. Only those participants available at the specified time points were analyzed.

End point type	Secondary

End point timeframe:

Baseline (Day 1) and Week 96

End point values	DTG + 3TC	DTG + TDF/FTC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	359[128]	358[129]		
Units: Scores on a scale				
arithmetic mean (standard error)	4.4 (± 0.45)	5.1 (± 0.52)		

Notes:

[128] - ITT-E Population.

[129] - ITT-E Population.

Statistical analyses

Statistical analysis title	Subject Analysis

Statistical analysis description:

Week 96. Covariates adjusted: Treatment, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count and Baseline EQ-5D utility, treatment*visit and Baseline EQ-5D utility*visit as factors and covariate, with visit as the repeated factor.

Comparison groups	DTG + 3TC v DTG + TDF/FTC
Number of subjects included in analysis	717
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.318
Method	MMRM
Parameter estimate	Mean difference (net)
Point estimate	-0.7

Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.1
upper limit	0.7

Secondary: Change From Baseline in EQ-5D-5L Thermometer Scores at Week 144

End point title	Change From Baseline in EQ-5D-5L Thermometer Scores at Week 144

End point description:

EQ-5D-5L questionnaire provided a profile of participant function and a global health state rating. The five-item measure has one question assessing each of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. EQ-5D-5L included EQ visual Analogue scale (EQ VAS) 'Thermometer' which provided Self-rated current health status. Score ranges from 0 (worst imaginable health state) to 100 (best imaginable health state). MMRM was run on the LOCF dataset, using the observed margins (OM) option. Baseline was the latest pre-dose assessment value and change from Baseline=post-dose value minus Baseline value. Adjusted mean and standard error is presented. Only those participants available at the specified time points were analyzed.

End point type	Secondary

End point timeframe:

Baseline (Day 1) and Week 144

End point values	DTG + 3TC - Double-blind Phase + Open-label Phase	DTG + TDF/FTC - Double-blind Phase + Open-label Phase		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	359[130]	358[131]		
Units: Scores on a scale				
arithmetic mean (standard error)	4.8 (± 0.44)	4.5 (± 0.51)		

Notes:

[130] - ITT-E Population.

[131] - ITT-E Population.

Statistical analyses

Statistical analysis title	Subject Analysis

Statistical analysis description:

Week 144. Covariates adjusted: Treatment, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count and Baseline EQ-5D utility, treatment*visit and Baseline EQ-5D utility*visit as factors and covariate, with visit as the repeated factor.

Comparison groups	DTG + 3TC - Double-blind Phase + Open-label Phase v DTG + TDF/FTC - Double-blind Phase + Open-label Phase

Number of subjects included in analysis	717
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.674
Method	MMRM
Parameter estimate	Mean difference (net)
Point estimate	0.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1
upper limit	1.6

Adverse events

Adverse events information

Timeframe for reporting adverse events:

All-cause mortality, SAEs and non-SAEs were collected up to Week 148 in Double-blind Phase + Open-label Phase and from Week 148 to Week 280 in Continuation Phase

Adverse event reporting additional description:

All-cause mortality, SAEs and non-SAEs were reported for the Safety Population for the Double-blind Phase and Double-blind Phase + Open-label Phase. Safety-Continuation Population was used for the Continuation Phase (which comprised of all participants who received at least 1 dose of study treatment after entering the Continuation Phase).

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	25.0

Reporting groups

Reporting group title	DTG + 3TC - Double-blind Phase + Open-label Phase

Reporting group description:

Participants received a two-drug regimen of DTG + 3TC administered orally, once daily until Week 96 in double-blind phase and participants continued to receive DTG + 3TC from Week 96 to Week 148 in an open-label phase.

Reporting group title	DTG + TDF/FTC - Double-blind Phase + Open-label Phase

Reporting group description:

Participants received a three-drug regimen of DTG + TDF/FTC FDC administered orally, once daily until Week 96 in double-blind phase and participants continued to receive DTG + TDF/FTC FDC from Week 96 to Week 148 in an open-label phase.

Reporting group title	DTG + 3TC - Continuation Phase

Reporting group description:

Participants received a DTG + 3TC administered orally, once daily from Week 148 to Week 280 in a continuation phase.

Serious adverse events	DTG + 3TC - Double-blind Phase + Open-label Phase	DTG + TDF/FTC - Double-blind Phase + Open-label Phase	DTG + 3TC - Continuation Phase
Total subjects affected by serious adverse events			
subjects affected / exposed	39 / 360 (10.83%)	47 / 359 (13.09%)	9 / 252 (3.57%)
number of deaths (all causes)	2	1	0
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Anogenital warts			
subjects affected / exposed	2 / 360 (0.56%)	3 / 359 (0.84%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
B-cell lymphoma			

subjects affected / exposed	1 / 360 (0.28%)	0 / 359 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Burkitt's lymphoma			
subjects affected / exposed	1 / 360 (0.28%)	0 / 359 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Basal cell carcinoma			
subjects affected / exposed	0 / 360 (0.00%)	1 / 359 (0.28%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal cancer stage 0			
subjects affected / exposed	1 / 360 (0.28%)	0 / 359 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Non-Hodgkin's lymphoma			
subjects affected / exposed	0 / 360 (0.00%)	1 / 359 (0.28%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Death			
subjects affected / exposed	0 / 360 (0.00%)	1 / 359 (0.28%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Immune system disorders			
Jarisch-Herxheimer reaction			
subjects affected / exposed	0 / 360 (0.00%)	0 / 359 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Asthma			

subjects affected / exposed	0 / 360 (0.00%)	1 / 359 (0.28%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 360 (0.00%)	0 / 359 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Suicidal ideation			
subjects affected / exposed	1 / 360 (0.28%)	4 / 359 (1.11%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	1 / 1	2 / 6	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicide attempt			
subjects affected / exposed	5 / 360 (1.39%)	2 / 359 (0.56%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 5	1 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Alcoholic psychosis			
subjects affected / exposed	0 / 360 (0.00%)	1 / 359 (0.28%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Substance-induced psychotic disorder			
subjects affected / exposed	0 / 360 (0.00%)	1 / 359 (0.28%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Major depression			
subjects affected / exposed	1 / 360 (0.28%)	0 / 359 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Contusion			

subjects affected / exposed	0 / 360 (0.00%)	1 / 359 (0.28%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fracture of penis			
subjects affected / exposed	0 / 360 (0.00%)	1 / 359 (0.28%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fracture			
subjects affected / exposed	1 / 360 (0.28%)	0 / 359 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower limb fracture			
subjects affected / exposed	1 / 360 (0.28%)	0 / 359 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury			
subjects affected / exposed	1 / 360 (0.28%)	0 / 359 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intentional overdose			
subjects affected / exposed	0 / 360 (0.00%)	1 / 359 (0.28%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural complication			
subjects affected / exposed	0 / 360 (0.00%)	1 / 359 (0.28%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Penetrating abdominal trauma			
subjects affected / exposed	0 / 360 (0.00%)	1 / 359 (0.28%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple injuries			

subjects affected / exposed	0 / 360 (0.00%)	1 / 359 (0.28%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Radius fracture

subjects affected / exposed	1 / 360 (0.28%)	0 / 359 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Multiple fractures

subjects affected / exposed	0 / 360 (0.00%)	1 / 359 (0.28%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Upper limb fracture

subjects affected / exposed	0 / 360 (0.00%)	1 / 359 (0.28%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Thermal burn

subjects affected / exposed	1 / 360 (0.28%)	0 / 359 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Joint dislocation

subjects affected / exposed	0 / 360 (0.00%)	1 / 359 (0.28%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Rib fracture

subjects affected / exposed	1 / 360 (0.28%)	0 / 359 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Traumatic arthritis

subjects affected / exposed	1 / 360 (0.28%)	0 / 359 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Cardiac disorders

Acute myocardial infarction

subjects affected / exposed	1 / 360 (0.28%)	0 / 359 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Tachycardia			
subjects affected / exposed	0 / 360 (0.00%)	1 / 359 (0.28%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure			
subjects affected / exposed	0 / 360 (0.00%)	0 / 359 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericarditis			
subjects affected / exposed	0 / 360 (0.00%)	1 / 359 (0.28%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Sciatica			
subjects affected / exposed	1 / 360 (0.28%)	1 / 359 (0.28%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Generalised tonic-clonic seizure			
subjects affected / exposed	1 / 360 (0.28%)	0 / 359 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	0 / 360 (0.00%)	2 / 359 (0.56%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 360 (0.00%)	0 / 359 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epilepsy			

subjects affected / exposed	0 / 360 (0.00%)	1 / 359 (0.28%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoaesthesia			
subjects affected / exposed	0 / 360 (0.00%)	1 / 359 (0.28%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Migraine with aura			
subjects affected / exposed	0 / 360 (0.00%)	1 / 359 (0.28%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Ophthalmic vein thrombosis			
subjects affected / exposed	1 / 360 (0.28%)	0 / 359 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	1 / 360 (0.28%)	1 / 359 (0.28%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal hernia			
subjects affected / exposed	0 / 360 (0.00%)	1 / 359 (0.28%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	1 / 360 (0.28%)	0 / 359 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematemesis			
subjects affected / exposed	0 / 360 (0.00%)	1 / 359 (0.28%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			

subjects affected / exposed	1 / 360 (0.28%)	0 / 359 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholecystitis acute			
subjects affected / exposed	0 / 360 (0.00%)	3 / 359 (0.84%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholelithiasis			
subjects affected / exposed	0 / 360 (0.00%)	1 / 359 (0.28%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatotoxicity			
subjects affected / exposed	1 / 360 (0.28%)	0 / 359 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gallbladder rupture			
subjects affected / exposed	1 / 360 (0.28%)	0 / 359 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Urethral meatus stenosis			
subjects affected / exposed	0 / 360 (0.00%)	1 / 359 (0.28%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydronephrosis			
subjects affected / exposed	1 / 360 (0.28%)	1 / 359 (0.28%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Calculus urinary			
subjects affected / exposed	0 / 360 (0.00%)	1 / 359 (0.28%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue			

disorders			
Intervertebral disc protrusion			
subjects affected / exposed	0 / 360 (0.00%)	1 / 359 (0.28%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Acute hepatitis C			
subjects affected / exposed	2 / 360 (0.56%)	1 / 359 (0.28%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	1 / 360 (0.28%)	2 / 359 (0.56%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis A			
subjects affected / exposed	3 / 360 (0.83%)	3 / 359 (0.84%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 3	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacterial colitis			
subjects affected / exposed	0 / 360 (0.00%)	1 / 359 (0.28%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal abscess			
subjects affected / exposed	0 / 360 (0.00%)	1 / 359 (0.28%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erysipelas			
subjects affected / exposed	0 / 360 (0.00%)	1 / 359 (0.28%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epididymitis			
subjects affected / exposed	1 / 360 (0.28%)	0 / 359 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Salmonellosis			
subjects affected / exposed	1 / 360 (0.28%)	0 / 359 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Soft tissue infection			
subjects affected / exposed	0 / 360 (0.00%)	1 / 359 (0.28%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia bacterial			
subjects affected / exposed	0 / 360 (0.00%)	1 / 359 (0.28%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	1 / 360 (0.28%)	0 / 359 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tuberculous pleurisy			
subjects affected / exposed	1 / 360 (0.28%)	0 / 359 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis C			
subjects affected / exposed	0 / 360 (0.00%)	0 / 359 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Varicella zoster virus infection			
subjects affected / exposed	1 / 360 (0.28%)	0 / 359 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19			
subjects affected / exposed	0 / 360 (0.00%)	0 / 359 (0.00%)	3 / 252 (1.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic tonsillitis			

subjects affected / exposed	0 / 360 (0.00%)	0 / 359 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	1 / 360 (0.28%)	1 / 359 (0.28%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
subjects affected / exposed	0 / 360 (0.00%)	1 / 359 (0.28%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis orbital			
subjects affected / exposed	0 / 360 (0.00%)	1 / 359 (0.28%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enteritis infectious			
subjects affected / exposed	1 / 360 (0.28%)	0 / 359 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis cryptosporidial			
subjects affected / exposed	1 / 360 (0.28%)	0 / 359 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Labyrinthitis			
subjects affected / exposed	1 / 360 (0.28%)	0 / 359 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Perirectal abscess			
subjects affected / exposed	0 / 360 (0.00%)	1 / 359 (0.28%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonitis			

subjects affected / exposed	0 / 360 (0.00%)	1 / 359 (0.28%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 360 (0.00%)	2 / 359 (0.56%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pharyngitis			
subjects affected / exposed	0 / 360 (0.00%)	1 / 359 (0.28%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syphilis			
subjects affected / exposed	1 / 360 (0.28%)	0 / 359 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Shigella infection			
subjects affected / exposed	0 / 360 (0.00%)	1 / 359 (0.28%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 2 %

Non-serious adverse events	DTG + 3TC - Double-blind Phase + Open-label Phase	DTG + TDF/FTC - Double-blind Phase + Open-label Phase	DTG + 3TC - Continuation Phase
Total subjects affected by non-serious adverse events			
subjects affected / exposed	273 / 360 (75.83%)	276 / 359 (76.88%)	45 / 252 (17.86%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Anogenital warts			
subjects affected / exposed	10 / 360 (2.78%)	15 / 359 (4.18%)	0 / 252 (0.00%)
occurrences (all)	13	17	0
Vascular disorders			
Hypertension			
subjects affected / exposed	14 / 360 (3.89%)	5 / 359 (1.39%)	0 / 252 (0.00%)
occurrences (all)	16	5	0
General disorders and administration			

site conditions			
Influenza like illness			
subjects affected / exposed	16 / 360 (4.44%)	11 / 359 (3.06%)	0 / 252 (0.00%)
occurrences (all)	20	14	0
Fatigue			
subjects affected / exposed	10 / 360 (2.78%)	9 / 359 (2.51%)	0 / 252 (0.00%)
occurrences (all)	13	9	0
Pyrexia			
subjects affected / exposed	11 / 360 (3.06%)	9 / 359 (2.51%)	0 / 252 (0.00%)
occurrences (all)	11	12	0
Asthenia			
subjects affected / exposed	10 / 360 (2.78%)	14 / 359 (3.90%)	0 / 252 (0.00%)
occurrences (all)	12	14	0
Reproductive system and breast disorders			
Erectile dysfunction			
subjects affected / exposed	9 / 360 (2.50%)	4 / 359 (1.11%)	0 / 252 (0.00%)
occurrences (all)	9	4	0
Respiratory, thoracic and mediastinal disorders			
Oropharyngeal pain			
subjects affected / exposed	17 / 360 (4.72%)	16 / 359 (4.46%)	0 / 252 (0.00%)
occurrences (all)	21	17	0
Cough			
subjects affected / exposed	11 / 360 (3.06%)	15 / 359 (4.18%)	0 / 252 (0.00%)
occurrences (all)	12	15	0
Rhinorrhoea			
subjects affected / exposed	3 / 360 (0.83%)	10 / 359 (2.79%)	0 / 252 (0.00%)
occurrences (all)	5	11	0
Psychiatric disorders			
Insomnia			
subjects affected / exposed	17 / 360 (4.72%)	23 / 359 (6.41%)	0 / 252 (0.00%)
occurrences (all)	17	28	0
Anxiety			
subjects affected / exposed	17 / 360 (4.72%)	18 / 359 (5.01%)	0 / 252 (0.00%)
occurrences (all)	17	19	0
Depression			

subjects affected / exposed	12 / 360 (3.33%)	13 / 359 (3.62%)	0 / 252 (0.00%)
occurrences (all)	14	16	0
Investigations			
Weight increased			
subjects affected / exposed	10 / 360 (2.78%)	9 / 359 (2.51%)	0 / 252 (0.00%)
occurrences (all)	10	10	0
Injury, poisoning and procedural complications			
Ligament sprain			
subjects affected / exposed	8 / 360 (2.22%)	6 / 359 (1.67%)	0 / 252 (0.00%)
occurrences (all)	8	6	0
Nervous system disorders			
Headache			
subjects affected / exposed	33 / 360 (9.17%)	44 / 359 (12.26%)	0 / 252 (0.00%)
occurrences (all)	49	60	0
Dizziness			
subjects affected / exposed	9 / 360 (2.50%)	18 / 359 (5.01%)	0 / 252 (0.00%)
occurrences (all)	11	20	0
Gastrointestinal disorders			
Nausea			
subjects affected / exposed	16 / 360 (4.44%)	31 / 359 (8.64%)	0 / 252 (0.00%)
occurrences (all)	17	33	0
Diarrhoea			
subjects affected / exposed	49 / 360 (13.61%)	53 / 359 (14.76%)	0 / 252 (0.00%)
occurrences (all)	55	61	0
Abdominal pain			
subjects affected / exposed	9 / 360 (2.50%)	17 / 359 (4.74%)	0 / 252 (0.00%)
occurrences (all)	10	17	0
Haemorrhoids			
subjects affected / exposed	16 / 360 (4.44%)	12 / 359 (3.34%)	0 / 252 (0.00%)
occurrences (all)	17	12	0
Constipation			
subjects affected / exposed	9 / 360 (2.50%)	14 / 359 (3.90%)	0 / 252 (0.00%)
occurrences (all)	9	14	0
Toothache			
subjects affected / exposed	7 / 360 (1.94%)	14 / 359 (3.90%)	0 / 252 (0.00%)
occurrences (all)	8	15	0

Vomiting			
subjects affected / exposed	11 / 360 (3.06%)	11 / 359 (3.06%)	0 / 252 (0.00%)
occurrences (all)	11	12	0
Abdominal pain upper			
subjects affected / exposed	5 / 360 (1.39%)	9 / 359 (2.51%)	0 / 252 (0.00%)
occurrences (all)	6	13	0
Gastrooesophageal reflux disease			
subjects affected / exposed	8 / 360 (2.22%)	9 / 359 (2.51%)	0 / 252 (0.00%)
occurrences (all)	9	10	0
Gastritis			
subjects affected / exposed	9 / 360 (2.50%)	7 / 359 (1.95%)	0 / 252 (0.00%)
occurrences (all)	10	7	0
Odynophagia			
subjects affected / exposed	2 / 360 (0.56%)	9 / 359 (2.51%)	0 / 252 (0.00%)
occurrences (all)	5	10	0
Anogenital dysplasia			
subjects affected / exposed	8 / 360 (2.22%)	4 / 359 (1.11%)	0 / 252 (0.00%)
occurrences (all)	10	4	0
Proctitis			
subjects affected / exposed	6 / 360 (1.67%)	8 / 359 (2.23%)	0 / 252 (0.00%)
occurrences (all)	8	9	0
Dental caries			
subjects affected / exposed	8 / 360 (2.22%)	2 / 359 (0.56%)	0 / 252 (0.00%)
occurrences (all)	8	2	0
Irritable bowel syndrome			
subjects affected / exposed	8 / 360 (2.22%)	1 / 359 (0.28%)	0 / 252 (0.00%)
occurrences (all)	10	1	0
Skin and subcutaneous tissue disorders			
Rash			
subjects affected / exposed	10 / 360 (2.78%)	13 / 359 (3.62%)	0 / 252 (0.00%)
occurrences (all)	13	16	0
Urticaria			
subjects affected / exposed	8 / 360 (2.22%)	13 / 359 (3.62%)	0 / 252 (0.00%)
occurrences (all)	12	15	0
Pruritus			

subjects affected / exposed	6 / 360 (1.67%)	11 / 359 (3.06%)	0 / 252 (0.00%)
occurrences (all)	9	12	0

Renal and urinary disorders

Dysuria

subjects affected / exposed	10 / 360 (2.78%)	3 / 359 (0.84%)	0 / 252 (0.00%)
occurrences (all)	10	3	0

Musculoskeletal and connective tissue disorders

Back pain

subjects affected / exposed	27 / 360 (7.50%)	23 / 359 (6.41%)	0 / 252 (0.00%)
occurrences (all)	32	30	0

Arthralgia

subjects affected / exposed	17 / 360 (4.72%)	25 / 359 (6.96%)	0 / 252 (0.00%)
occurrences (all)	21	26	0

Neck pain

subjects affected / exposed	10 / 360 (2.78%)	6 / 359 (1.67%)	0 / 252 (0.00%)
occurrences (all)	10	11	0

Myalgia

subjects affected / exposed	8 / 360 (2.22%)	7 / 359 (1.95%)	0 / 252 (0.00%)
occurrences (all)	9	12	0

Infections and infestations

Pharyngitis

subjects affected / exposed	24 / 360 (6.67%)	33 / 359 (9.19%)	0 / 252 (0.00%)
occurrences (all)	31	35	0

Upper respiratory tract infection

subjects affected / exposed	47 / 360 (13.06%)	28 / 359 (7.80%)	7 / 252 (2.78%)
occurrences (all)	75	44	7

Nasopharyngitis

subjects affected / exposed	44 / 360 (12.22%)	69 / 359 (19.22%)	0 / 252 (0.00%)
occurrences (all)	59	103	0

Bronchitis

subjects affected / exposed	12 / 360 (3.33%)	21 / 359 (5.85%)	0 / 252 (0.00%)
occurrences (all)	14	24	0

Gastroenteritis

subjects affected / exposed	21 / 360 (5.83%)	20 / 359 (5.57%)	6 / 252 (2.38%)
occurrences (all)	21	25	6

Tonsillitis

subjects affected / exposed	13 / 360 (3.61%)	9 / 359 (2.51%)	0 / 252 (0.00%)
occurrences (all)	14	13	0
Gonorrhoea			
subjects affected / exposed	12 / 360 (3.33%)	12 / 359 (3.34%)	0 / 252 (0.00%)
occurrences (all)	14	15	0
Respiratory tract infection viral			
subjects affected / exposed	14 / 360 (3.89%)	12 / 359 (3.34%)	8 / 252 (3.17%)
occurrences (all)	20	19	10
Syphilis			
subjects affected / exposed	26 / 360 (7.22%)	30 / 359 (8.36%)	10 / 252 (3.97%)
occurrences (all)	30	34	11
Influenza			
subjects affected / exposed	16 / 360 (4.44%)	25 / 359 (6.96%)	0 / 252 (0.00%)
occurrences (all)	17	27	0
COVID-19			
subjects affected / exposed	0 / 360 (0.00%)	0 / 359 (0.00%)	15 / 252 (5.95%)
occurrences (all)	0	0	15
Suspected COVID-19			
subjects affected / exposed	0 / 360 (0.00%)	0 / 359 (0.00%)	7 / 252 (2.78%)
occurrences (all)	0	0	8
Anal chlamydia infection			
subjects affected / exposed	10 / 360 (2.78%)	16 / 359 (4.46%)	0 / 252 (0.00%)
occurrences (all)	12	21	0
Sinusitis			
subjects affected / exposed	12 / 360 (3.33%)	12 / 359 (3.34%)	0 / 252 (0.00%)
occurrences (all)	14	13	0
Urinary tract infection			
subjects affected / exposed	11 / 360 (3.06%)	9 / 359 (2.51%)	0 / 252 (0.00%)
occurrences (all)	14	12	0
Proctitis gonococcal			
subjects affected / exposed	9 / 360 (2.50%)	9 / 359 (2.51%)	0 / 252 (0.00%)
occurrences (all)	12	11	0
Respiratory tract infection			
subjects affected / exposed	10 / 360 (2.78%)	8 / 359 (2.23%)	0 / 252 (0.00%)
occurrences (all)	12	10	0
Secondary syphilis			

subjects affected / exposed	7 / 360 (1.94%)	10 / 359 (2.79%)	0 / 252 (0.00%)
occurrences (all)	7	11	0

Folliculitis

subjects affected / exposed	8 / 360 (2.22%)	8 / 359 (2.23%)	0 / 252 (0.00%)
occurrences (all)	16	9	0

Chlamydial infection

subjects affected / exposed	10 / 360 (2.78%)	13 / 359 (3.62%)	0 / 252 (0.00%)
occurrences (all)	13	13	0

Rhinitis

subjects affected / exposed	5 / 360 (1.39%)	16 / 359 (4.46%)	0 / 252 (0.00%)
occurrences (all)	6	18	0

Genital herpes

subjects affected / exposed	4 / 360 (1.11%)	10 / 359 (2.79%)	0 / 252 (0.00%)
occurrences (all)	4	14	0

Gingivitis

subjects affected / exposed	9 / 360 (2.50%)	4 / 359 (1.11%)	0 / 252 (0.00%)
occurrences (all)	13	4	0

Oral herpes

subjects affected / exposed	9 / 360 (2.50%)	6 / 359 (1.67%)	0 / 252 (0.00%)
occurrences (all)	13	7	0

Conjunctivitis

subjects affected / exposed	6 / 360 (1.67%)	9 / 359 (2.51%)	0 / 252 (0.00%)
occurrences (all)	6	10	0

Herpes zoster

subjects affected / exposed	8 / 360 (2.22%)	5 / 359 (1.39%)	0 / 252 (0.00%)
occurrences (all)	8	5	0

Urethritis

subjects affected / exposed	8 / 360 (2.22%)	5 / 359 (1.39%)	0 / 252 (0.00%)
occurrences (all)	9	5	0

Urethritis gonococcal

subjects affected / exposed	3 / 360 (0.83%)	8 / 359 (2.23%)	0 / 252 (0.00%)
occurrences (all)	4	9	0

Cellulitis

subjects affected / exposed	8 / 360 (2.22%)	2 / 359 (0.56%)	0 / 252 (0.00%)
occurrences (all)	10	3	0

Viral infection

subjects affected / exposed	4 / 360 (1.11%)	8 / 359 (2.23%)	0 / 252 (0.00%)
occurrences (all)	4	8	0

Metabolism and nutrition disorders
   Vitamin D deficiency

subjects affected / exposed	28 / 360 (7.78%)	20 / 359 (5.57%)	0 / 252 (0.00%)
occurrences (all)	29	20	0

   Hypertriglyceridaemia

subjects affected / exposed	9 / 360 (2.50%)	6 / 359 (1.67%)	0 / 252 (0.00%)
occurrences (all)	10	6	0

   Decreased appetite

subjects affected / exposed	8 / 360 (2.22%)	3 / 359 (0.84%)	0 / 252 (0.00%)
occurrences (all)	8	3	0

   Dyslipidaemia

subjects affected / exposed	8 / 360 (2.22%)	3 / 359 (0.84%)	0 / 252 (0.00%)
occurrences (all)	8	3	0

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
29 November 2017	Amendment 1: Double barrier method of contraception (male condom combined with a vaginal spermicide) was added as a permitted method for preventing pregnancy in females of reproductive potential. Exclusion criterion 15 (limitations on investigational drug use) was broadened to include additional countries as needed. Inclusion of Portugal was required by Portuguese National Ethics Committee for Clinical Research. Assessment of weight at Weeks 96 and 144 was added to monitor incidence of significant weight gain with DTG use. Assessment of inflammation biomarkers ([interleukin {IL}-6, high sensitivity C-reactive protein {hs-CRP}) at Day1, and Weeks48, 96, 144 and Assessment of telomere length at Day 1, and Weeks 96 and 144, were added as new exploratory endpoints. For clarification purposes, peripheral blood mononuclear cell (PBMC) sample in Time and Events table and Human immuno deficiency virus [HIV-1] Exploratory Analyses was renamed as a whole blood sample. The Day 1 PBMC sample (now named whole blood sample) originally designated for virology use was additionally designated for telomere length measurement, where possible. Additional whole blood samples were added for measurement of telomere length at Week 96 and Week 144. A description of commercial image DTG tablets was added to Section 6.1 (Investigational Product and Other Study Treatment) to allow use of commercial material as well as clinical trial material. The physical description for open-label lamivudine in Section 6.1 was corrected. Standard procedures for forwarding pregnancy information to the Antiretroviral Pregnancy Register were added. For clarification purposes, the AE severity grading's in Appendix 7, Section 12.7.6 (Evaluating adverse events [AEs] and serious adverse events [SAEs]) were updated to be consistent with Appendix 6, Section 12.6. (Division of AIDS table for Grading Severity of Adult and Pediatric AEs). This change has no impact on the investigators evaluation of AEs.
14 June 2018	Amendment 2: Changes were made to the protocol to manage and mitigate risks following identification of a potential safety issue related to neural tube defects in infants born to women with exposure to dolutegravir at the time of conception. Changes were also made to update the references to the DTG Investigator's Brochure to reflect the most current versions. • The Risk Assessment table (Section 4.6.1) was updated to include language regarding risk and mitigation of neural tube defects. • The withdrawal criteria (Section 5.4) were updated to include a reminder that females of reproductive potential who change their minds and desire to be pregnant, or who state they no longer are willing to comply with the approved pregnancy avoidance methods, should also be withdrawn from the study. • The Time and Events table (Section 7.1). was updated to include a reminder for investigators to check at every visit that females of reproductive potential are avoiding pregnancy. • The modified list of highly effective methods for avoiding pregnancy in Females of Reproductive Potential (Section 12.9.1) was updated to exclude the double barrier method of contraception, which does not meet updated GlaxoSmithKline/ViiV criteria for a highly effective method.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

 None reported